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Abstract 
The increased energy requirements and the decreased dry matter intake during late gestation and 
early lactation, in particular relative to the requirement, cause a catabolic state in the dairy cow, 
characterized by a distinct negative energy balance (NEB). During NEB increased concentrations 
in blood of non-esterified fatty acids (NEFA) are detectable. Subsequently, ketone bodies are 
produced in the liver. β-hydroxybutyrate (BHB) is the most stable ketone body in blood, 
therefore it is usually used to define a ketotic status, with 1.2 mM BHB in serum suggested as 
cut-off point for subclinical ketosis. The aim of the present dissertation was to induce subclinical 
ketosis in lactating cows to test potential therapeutical or prophylactic measures. Owing to a body 
condition score (BCS) of at least 3.0 six weeks before calving, a high energy diet ante partum 
(concentrate proportion of 60%) and a decreased energy supply post partum, 80% of the cows 
developed ketosis (81% subclinical, 19% clinical ketosis). The success of the animal model 
allowed for a well-controlled observation of different variables, related to metabolism and the 
immune system. Cows of subclinical ketosis had higher blood concentrations of NEFA, BHB and 
liver function enzymes, as well as higher liver lipid contents (e.g. 154 mg/g in the 2
nd
 week post 
partum) than cows which were fed adequately and stayed metabolically healthy during the 
experimental trial. Moreover, subclinically ketotic cows had higher milk yields (Δ = 4.4 kg/day) 
and a fat:protein ratio in milk > 1.5, which also coincides a high lipolysis. Variables about 
immune function were slightly influenced by the ketotic metabolism. In in vitro tests peripheral 
blood mononuclear cells (PBMC) of cows not pre-stressed by ketosis in vivo responded more 
sensitively to increased concentrations of BHB as evidenced by both, the proliferative capability 
and the increased release of nitric oxide in the PBMC supernatant. The results indicate that even 
slightly diminished immune cell reactions might imply an immunosuppression during 
periparturient period and confirmed statements that beside NEFA, BHB also elicits effects on 
immune cells.    
For further investigations and in relation to find new possibilities for ketosis therapy, a dipeptidyl 
peptidase-4 (DPP4) inhibitor (BI 14332) was tested. The inhibition of DPP4 via specific 
inhibitors is known to result in improved insulin sensitivity and decreased accumulation of 
hepatic fat in rodents and type II diabetic human patients. With first occurrence of serum BHB 
concentrations ≥ 1.2 mM BI 14332 was administered daily for 7 days (intravenous, 0.3 mg/kg 
body weight). The treatment did not alter the main markers of ketosis (BHB, liver lipid content), 
but NEFA and triglyceride concentrations in blood were decreased after the treatment. Therefore, 
a positive impact on the pathways of energy metabolism, resulting in a reduced NEB-induced 
lipolysis may be assumed. Furthermore, the results suggest that the DPP4 inhibition acts also at 
cellular level. The increase in the lymphocyte CD4
+
/CD8
+
 ratio for treated versus untreated cows 
was less strong and indicated that the peripartal immune dysregulation of ketotic cows may be 
positively modulated by BI 14332. A moderate correlation between NEFA and the CD4
+
/CD8
+
 
ratio (r = 0.40) clarified how close changes at the biochemical level are connected to immune 
dysregulation.  
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Kurzfassung 
Während der Transitphase weisen Milchkühe einen erhöhten Energiebedarf auf, wobei die 
Futteraufnahme gleichzeitig gesenkt ist. Es kommt verstärkt zum Abbau von Körperreserven, 
insbesondere von Depotfett. Die resultierende negative Energiebilanz (NEB) ist gekennzeichnet 
durch hohe Konzentrationen an nicht-veresterten Fettsäuren (NEFA) im Blut. Mit steigenden 
NEFA-Konzentrationen werden diese in der Leber oxidiert (β-Oxidation) und über das dabei 
entstehende Acetyl-CoA in Ketonkörper umgewandelt (Ketogenese). Ketonkörper werden von 
der Leber in den Blutkreislauf abgegeben und stellen eine Energiequelle für verschiedene Organe 
(z.B. das Gehirn) dar. β-Hydroxybutyrat (BHB) gilt als bedeutendster „Ketonkörper“ und als 
Indikator für subklinische (BHB im Blut > 1.2 mM) und klinische Ketosen (BHB im Blut ≥ 3.0 
mM). Ziel der vorliegenden Dissertation war die Schaffung einer Tiermodells zur Induktion 
subklinischer Ketosen bei der Milchkuh, um so unter kontrollierten Bedingungen den ketotischen 
Stoffwechsel und mögliche Auswirkungen auf die Immunantwort zu untersuchen. Dabei wurden 
Kühe mit einer Körperkondition (BCS) von mindestens 3.0 für die letzten 6 Wochen der 
Trächtigkeit mit einer hochenergetischen Futterration versorgt (7.7 MJ NEL/kg Trockenmasse). 
Post partum erfolgte eine verzögerte Steigerung der Energiezufuhr um die postpartale Lipolyse 
zusätzlich zu stimulieren. Insgesamt wiesen 80% der Kühe eine Ketose auf (81% subklinisch, 
19% klinisch) und zeigten höhere Blutkonzentrationen an BHB, NEFA und ausgewählten 
Leberenzymen als gesunde, normalkonditionierte Kühe der Kontrollgruppe. Subklinische Kühe 
gaben zudem mehr Milch (Δ = 4.4 kg/Tag), wobei der Fett/Protein-Quotient der Milch über 1.5 
lag, was auf eine übermäßige Lipolyse hinweist. Gravierende Auswirkungen auf immunologische 
Parameter konnten nicht gezeigt werden, jedoch ließ sich aus den durchgeführten in vitro-
Untersuchungen ableiten, dass bereits eine subklinische Ketose die Immunzellreaktionen 
vermindert und so das Risiko von Folgeerkrankungen erhöht sein kann.  
Mit dem Ziel neue Therapiemaßnahmen bei Ketose zu entwickeln, wurde erstmalig der Einsatz 
eines Dipeptidylpeptidase-4 (DPP4) Inhibitors (BI 14332) getestet. Untersuchungen bei Nagern 
und Diabetes-Typ II-Patienten zeigen, dass durch eine DPP4-Inhibierung die Insulinsensitivität 
verbessert werden kann, während es in der Leber gleichzeitig zu reduzierten Fetteinlagerungen 
kommt. In der vorliegenden Dissertation wurden subklinisch ketotische Kühe über 7 Tage (1 x 
täglich) mit dem DPP4-Inhibitor behandelt (intravenös, 0.3 mg/kg Lebendmasse). Durch die 
Behandlung konnte der Gehalt an BHB im Blut und der Leberfettgehalt der Kühe nicht 
beeinflusst werden, jedoch waren die Konzentrationen an NEFA und Triglyceriden mit 
Behandlungsende reduziert. Die BI 14332-Behandlung lässt einen positiven Einfluss auf den 
Energiestoffwechsel vermuten, so dass die durch die NEB induzierte Lipolyse leicht reduziert 
war. Auch Einflüsse auf zellulärer Ebene sind vorstellbar. So weist ein weniger starker Anstieg 
des CD4
+
/CD8
+
-Quotienten bei T-Lymphozyten auf eine verbesserte Immunregulation im 
peripartalen Zeitraum hin. Letztlich verdeutlicht der positive Zusammenhang der NEFA-
Konzentration im Blut mit dem CD4
+
/CD8
+
-Quotienten (r = 0.40) wie eng biochemische 
Veränderungen auch mit Dysregulationen des Immunsystem einhergehen und umgekehrt. 
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1. Introduction 
Ketosis is an important clinical or subclinical disease of the high yielding dairy cow, which 
occurs typically during early lactation. The pathogenesis of bovine ketosis is incompletely 
understood, but it requires the combination of intense adipose tissue mobilization with increased 
blood concentrations of free fatty acids and ketone bodies, as well as a high demand of glucose.  
1.1 Ketogenesis and ketosis in dairy cows 
To meet the requirements for maintenance and milk production, cows like other mammals are 
able to make use of two sources of nutrients – feed intake and body reserves. During ruminal 
microbial fermentation short-chain fatty acids are released. Of these, only propionate (one of the 
most abundant short-chain fatty acid with 15-40% of total released organic acids), valerate and 
isobutyrate can serve as glucogenic precursors for the net synthesis of glucose (Aschenbach et al., 
2011; Larsen and Kristensen, 2009). If the feed intake is insufficient to meet the energy 
requirements, ruminal production is insufficient to provide glucogenic precursors. An efficient 
gluconeogenesis is most important in high-yielding dairy cows because it is the major pathway 
for maintaining an adequate glucose supply for the mammary gland (Reynolds et al., 1988). In 
case of hypoglycemia, the mobilization of non-esterified fatty acids (NEFA) and glycerol via 
lipolysis from adipose tissue is induced. NEFA and glycerol are transported to the liver through 
the bloodstream. β-oxidation takes place in the hepatic mitochondria, where NEFA are 
metabolized to acetyl-CoA. Hepatic ketogenesis results from a lack of oxaloacetate necessary to 
condense with acetyl-CoA to enter the citric cycle. Therefore, the excess of acetyl-CoA is 
converted into the ketone body acetoacetate within three steps. Acetoacetate enters the blood, or 
is reduced to β-hydroxybutyrate (BHB). The alternative path of acetoacetate is spontaneous 
decarboxylation to acetone (Berg et al., 2002). Tissues other than the liver (notably brain, skeletal 
and cardiac muscle) can use ketone bodies, but the accumulation exceeds the rate of peripheral 
utilization and increased values in blood are detectable. The resulting condition is called ketosis. 
The ketone bodies acetoacetate and BHB are excreted in milk and urine; acetone is primarily 
expired by the lungs (e.g. von Soosten et al., 2015).  
Furthermore, feeding silage with high contents of butyric acid increases the risk of ketosis. This 
induced condition is sometimes called nutritional ketosis. Butyrate is a precursor of acetyl-CoA 
and is therefore ketogenic (Oetzel, 2007). Silages that are chopped too wet or that are low in 
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water-soluble carbohydrates favor growth of Clostridium sp. bacteria which ferment some 
carbohydrates to butyric acid instead of the desired lactic acid (Tveit et al., 1992).  
BHB is more stable in blood than acetoacetate or acetone and is therefore often used to 
characterize the ketotic status of the dairy cow. Depending on the literature, the most commonly 
used cut-off point for ketosis is 1.2 mM or 1.4 mM BHB in blood serum. This kind of ketosis is 
called subclinical ketosis as usually no clinical signs occur. Clinical ketosis normally involves 
much higher concentrations of BHB, about 3 mM or more (Duffield, 2000; Oetzel, 2007).   
Ketosis may be primary or secondary. Primary ketosis results as peripartal energy deficit and is 
therefore an integral part of the “fat cow syndrome”, respectively it is caused by a lack of glucose 
during the first weeks of lactation. Secondary ketosis is the result of diseases causing the 
reduction in appetite, like displaced abomasum, metritis or mastitis (Dirksen et al., 2012).  
1.1.1 The energy metabolism during early lactation 
In dairy cows, the metabolism needs to be adapted to the regular cyclic course related to calving 
and lactation. In the last part of lactation and the beginning of the dry period, the cow is usually 
in an anabolic stage and from a few weeks before to about one month after calving in a catabolic 
state (Holtenius and Holtenius, 1996). Figure 1 refers to the negative energy balance (NEB) and 
the loss of appetite, which are prerequisites for the onset of ketosis soon after parturition. The 
Figure describes the relationship of metabolic imbalances and the onset of inflammatory 
processes with compromised immune competence.  
In early lactation, glucose is taken up insulin-independently by the mammary gland. The ratio of 
growth hormone to insulin is high in blood, which induces mobilization of fatty acids from 
adipose tissue. Accompanying metabolic adaptations include increased hepatic gluconeogenesis, 
reduced glucose utilization by peripheral tissues and increased peripheral tissue utilization of 
NEFA and BHB. The liver re-esterifies NEFA to triglycerides (TG), which can be re-exported as 
part of very-low-density lipoproteins, but in condition of elevated hepatic NEFA uptake, TG 
accumulate. This feature contributes to a fatty liver. Hormones, such as adrenalin, noradrenalin 
and estrogen are positively associated with calving stress and support the increase of NEFA in 
blood and the synthesis of TG by the liver (Grummer, 1993). During fatty liver, metabolic 
imbalances become worse because hepatic ketogenesis, oxidative processes and gluconeogenesis 
from different gluconeogenic precursors are strongly decreased. The pancreatic insulin and 
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glucagon secretion and the peripheral glucose uptake are inhibited in cows with fatty liver (Bobe 
et al., 2004). Many of these cows had severe hepatic lipidosis, and insulin sensitivity decreased 
with increasing severity of ketosis (Ohtsuka et al., 2001). Especially cows selected for high milk 
yield are of risk to develop insulin resistance, which is also associated with greater body lipid 
mobilization and a lower body condition score (BCS) nadir (Roche, 2006; Smith and McNamara, 
1989). Furthermore, increased resistance of adipose tissue to insulin initiates NEFA mobilization, 
hence potentially creating a vicious cycle of NEFA mobilization and reduction of dry matter 
intake (DMI) during the late prepartum period (Grummer et al., 2004).  
 
Figure 1. Major interactions between the immune, endocrine and metabolic system in dairy cows 
during the transition period (adapted from Esposito et al., 2014). Inflammation post partum, high 
cellular metabolism and upregulated immune gene expression increase energy requirements in case of a 
reduced dry matter intake. NEFA = non-esterified fatty acids, BHB = β-hydroxybutyrate, TNF-α = tumor 
necrosis factor-α, IL-1 = interleukin 1. 
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1.1.2 Immune-modulatory consequences of ketosis 
According to LeBlanc (2010), ketosis may not have direct effects on the immune system but can 
indirectly affect the compromised immune response around calving. The metabolic effects of 
inflammation include adipose tissue mobilization, breakdown of liver glycogen, and liver TG 
accumulation. More specifically, tumor necrosis factor- α (TNF-α) is associated with hepatic 
lipidosis, impaired insulin sensitivity, and direct stimulation of lipolysis (Kushibiki et al., 2001; 
Ohtsuka et al., 2001). Further pro-inflammatory cytokines, such as interleukin (IL)-1 and IL-6, 
are known to trigger the acute phase reaction. Haptoglobin (Hp), as most important acute phase 
protein in cattle, is positively associated to NEFA and fatty liver (Saremi et al., 2012; Uchida et 
al., 1993) and a transiently higher body temperature around calving (Cooke and Bohnert, 2011). 
The production of reactive oxygen species in early lactating cows, accompanied by increased 
NEFA concentrations, stimulates excessive lipid peroxide formation, and both the transition to 
lactation and high body condition are associated with increased plasma markers of lipid 
peroxidation (Bernabucci et al., 2005). Reactive oxygen species are especially harmful to 
immune cells and can decrease the ability of the immune system to respond to infections (Spears 
and Weiss, 2008). Investigations of the lymphocyte function in case of ketosis were mainly 
focusing on direct effects of BHB and NEFA. In particular, high concentrations of NEFA 
decrease the proliferative capability of peripheral blood mononuclear cells (PBMC) and the 
production of interferon-γ, in vivo and in vitro (Scalia et al., 2006; Ster et al., 2012; 
Suriyasathaporn et al., 2000). For BHB, concentrations > 1.5 mM are considered critically with 
regard to the function of bovine myeloid and erythroid progenitor cells and to the oxidative burst 
activity of neutrophils (Hoeben et al., 1999; Hoeben et al., 1997). In contrast, even much higher 
BHB concentrations (up to 6.25 mM) did not suppress ConA-stimulated PBMC proliferation 
(Franklin et al., 1991) in vitro.  
1.2 Incidence and relevance of subclinical ketosis 
The primary risk period for hyperketonemia is commonly reported for the first two months of 
lactation (Duffield, 2000). More recent work showed that advances in genetics and feeding 
management have pushed the metabolic challenge closer to calving, namely in the first two 
weeks after calving (McArt et al., 2012a; Suthar et al., 2013). McArt et al. (2012a) reported an 
average incidence of subclinical ketosis of 43%, with a peak incidence at day 5 post partum (p.p., 
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29%). In Western Europe the herd average of ketosis is 39%, with highest values in France (53%) 
and lowest in the United Kingdom and Italy (both 31%; (Berge and Vertenten, 2014). To briefly 
summarize, the early incidence of subclinical ketosis during the early lactation was found to 
affect 40 to 60% of cows in herds undergoing repeated testing (Asl et al., 2011; Duffield et al., 
1998) and is much higher than the 2 to 15% incidence found with clinical ketosis (Duffield, 
2000).  
Cows with ketosis are at an increased risk of developing p.p. diseases, such as lameness, 
displaced abomasum, gastrointestinal disorders or metrits (Berge and Vertenten, 2014; Ospina et 
al., 2010a; Suthar et al., 2013). Each 0.1 mM increase in BHB concentrations in blood above 1.2 
mM increases the risk of displaced abomasum by 1.1 and the risk for a herd removal by 1.4 
(McArt et al., 2012b). Furthermore, subclinically ketotic cows have decreased milk yields with a 
high milk fat content and low milk protein in early lactation (Ospina et al., 2010b), as well as an 
impaired reproductive performance 50 to 100 days later, attributed to a delayed commencement 
of ovulation (Butler, 2003; Walsh et al., 2007). The negative impacts of subclinical ketosis result 
in an estimated economic loss of US $104 per case (McArt et al., 2014). 
1.3 Prevention 
Recommendations for prevention are focused on the nutritional management of the dry and the 
transition cow. Body condition should start to be managed in late lactation, when cows might 
become too fat. A BCS of 3.25 at calving is desirable to allow for adequate body fat reserves to 
support all energy requirements for maintenance, fetal growth and lactation while minimizing 
tissue energy mobilization and fatty acid infiltration to the liver (Ingvartsen and Moyes, 2013). 
Next to this, the avoidance of ketogenic feedstuffs and increased frequency of concentrate 
feeding are suggested as preventive measures (Gustafsson et al., 1995; Tveit et al., 1992). In 
addition to appropriate nutrition, feed additives might be useful to avoid ketosis. Well studied 
additives than reduce the risk of ketosis, are niacin (supplementation prior to calving), propylene 
glycol (prophylactical administration) or monensin (Duffield et al., 1998; Morey et al., 2011; 
Niehoff et al., 2009; Nielsen and Ingvartsen, 2004).  
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1.4 Therapeutic measures 
1.4.1 General aspects 
Treatment of ketosis aims at reestablishing normoglycemia and reducing serum ketone body 
concentrations. Administration (via intramuscular injection) of dextrose solution and 
glucocorticoids, like dexamethasone and isoflupredone acetate, also in combination with glucose 
as repeated measures, are common therapeutic options. According to Gordon et al. (2013), the 
most effective treatment is 300 mL of 100% propylene glycol orally once daily for 5 days. Cases 
of ketosis occurring during the first two weeks after calving are described as very refractory to 
therapy. Therefore, a long-acting insulin preparation may be beneficial, as insulin suppresses both 
adipose mobilization and ketogenesis (Gordon et al., 2013; Sakai et al., 1993). Nevertheless, the 
authors conclude, that there is still a lack of well-designed clinical trials for the treatment of 
ketosis. 
1.4.2 Dipeptidyl peptidase-4 and new therapeutic concepts 
Dipeptidyl peptidase-4 (DPP4), also known as CD 26, was discovered first in 1966 (Hopsu-Havu 
and Glenner, 1966). It is an intrinsic membrane-spanning glycoprotein and a serine exopeptidase, 
which prefers substrates with an amino-terminal proline or alanine at position 2. Dipeptidyl 
peptidase-4 plays a major role in glucose metabolism and is responsible for the degradation of the 
incretin hormones gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1; Drucker 
and Nauck, 2006). Both peptides reveal a highly conserved alanine at position 2. 
Further action of DPP4 is amplified by the multitude of bioactive substrates which act as 
biochemical messengers in many tissues, including the immune and the neuroendocrine system.  
1.4.2.1 The incretin metabolism and the enzymatic activity of DPP4 
The term “incretin effect” was originally used to describe the fact that an oral glucose load 
produces a greater insulin response than an isoglycemic intravenous glucose infusion. The 
difference between the two kinds of glucose administration was attributed to the incretin 
hormones GIP and GLP-1. The corresponding G-protein-coupled receptors are expressed on 
pancreatic α- and β-cells and different peripheral tissues, such as central nervous system, 
gastrointestinal tract, heart and lungs. Its activation increases cyclic adenosine monophosphate 
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(cAMP) levels and insulin secretion in a glucose dependent manner. A sustained incretin binding 
to the receptor increases insulin biosynthesis via activation of protein kinase A. In addition, GLP-
1 suppresses glucagon release from α-cells, which reduces the hepatic glucose production 
(Kazafeos, 2011). Nauck and colleges demonstrated a reduced incretin effect during type II 
diabetes and showed a preserved action of GLP-1 and a diminished GIP responsivity to glucose 
in clinical models of type II diabetes (Nauck, 1998; Nauck et al., 1993).  
 
Figure 2. Secretion and metabolism of glucagon-like peptide-1 (GLP-1; adapted from Cefalu, 2010 ). 
After food ingestion, GLP-1 is released by the small intestine in its active form (7-36) in plasma, which is 
rapidly degraded to the inactive form (9-36) by the enzyme dipeptidyl peptidas-4 (DPP4). Incretin therapy 
can increase available GLP-1 activity by the use of selective DPP4 inhibitors. GLP-1 acts on the 
pancreatic α- and β-cells to increase insulin release and to suppress glucagon release, than decreasing 
hepatic glucose production.  
Owing to this important issue, type II diabetes therapy aims to a continuous concentration of 
active GLP-1, circulating in blood in form of GLP-1 (7-36). It is released from the small 
intestine. Mentlein et al. (1993) were the first who identified DPP4 as the enzyme which is 
responsible for the enzymatic degeneration of GLP-1 in vitro. Within minutes of eating, 80 – 90 
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% of total plasma GLP-1 is inactive (= GLP-1 (9-36); Deacon et al., 1995). Therefore, incretin 
based therapies show great promise for the treatment of type II diabetes (Juillerat-Jeanneret, 
2014; White, 2008). Figure 2 shows the mechanism of active GLP-1 in consideration of DPP4 
inhibition, like it is well studied in rodents and humans. 
Relling and Reynolds (2007) were the first who detected GLP-1 and GIP in plasma of cows, with 
significantly increased concentrations after calving, while insulin and glucose concentrations 
were lower p.p. than ante partum (a.p.). Similar to monogastrics, dietary energy particularly from 
unsaturated fatty acids has been shown to enhance the secretion of GLP-1 in steers (Taylor-
Edwards et al., 2010). In dairy cows, the concentration of GLP-1 was unaffected by abomasal 
infusion of glucose (Larsen et al., 2010), but was increased after infusion of soybean oil and 
casein (Relling and Reynolds, 2008), respectively by feeding a diet with added unsaturated fatty 
acids (Bradford et al., 2008). The lipid-induced elevation in circulating GLP-1 is believed to play 
a role in the short-term control of feed intake in cattle (Bradford et al., 2008; Relling and 
Reynolds, 2008), but the wide range of tissues expressing the GLP-1 receptor (multitude of gut 
segments, pancreas, spleen and kidney) suggest that GLP-1 may have multiple physiological 
functions beyond the control of feed intake (Pezeshki et al., 2012). Expression of bovine DPP4 
shows a pattern of expression similar to that in humans, with highest values in jejunum and ileum 
(Connor et al., 2010). Studies show that the DPP4 expression and circulating GLP-1 
concentrations in blood are strongly regulated by the stage of lactation. Plasma concentrations of 
GLP-1 increase after calving (Relling and Reynolds, 2007). The DPP4 mRNA expression is 
lowest in prepubertal heifers, greatest in nonlactating cows, and intermediate among lactating 
cows (Connor et al., 2010).  
1.4.2.2 DPP4 and its role in immune function  
Next to GLP-1, there is a multitude of substrates for DPP4, e.g. various chemokines, 
neuropeptide Y, growth hormone releasing factor, insulin-like growth factor and prolactin 
(Schuppan et al., 2010). The cell surface expression of DPP4 is upregulated in activated human 
lymphocytes and correlates with the production of interferon-γ (Salgado et al., 2000).  
In 1993, DPP4 was identified as binding protein for adenosine deaminase (ADA). The ADA 
catalyzes the irreversible deamination of adenosine to inosine and is part of the cellular and 
humoral immunity. It is expressed in all tissues and mainly on T-lymphocytes. The model of 
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Morimoto and Schlossman (1998) describes a DPP4-ADA-adenosine-interaction in which DPP4 
modulates the concentration of extracellular adenosine, which provides negative signals to T-
cells (De Meester et al., 1999; Morimoto and Schlossman, 1998). Moreover, Yu et al. (2011) 
showed that DPP4 is able to enhance lymphocyte proliferation of humans in vitro, even 
independently of enzyme activity and ADA-binding. Fischer 344 CD26-deficiet rats have 
markedly reduced numbers of CD4
+
 T-cells and a decreased T-cell recruitment compared to wild-
type F344 (Kruschinski et al., 2005). In CD26 (-/-) mice, the cytokine response to pokeweed 
mitogen is altered with reduced concentrations of IL-2 and IL-4, as well as delayed production of 
interferon-γ (Yan et al., 2003). In brief, DPP4 contributes to the regulation, maturation and 
migration of CD4
+
 T-cells, natural killer cells, cytokine production, T-cell dependent antigen 
production and immunoglobulin isotype switching of B-cells (Gorrell et al., 2001; Yan et al., 
2003). 
1.4.3 Use of DPP4 inhibitors and general health claims 
Incretin-based therapies include both GLP-1 receptor agonists (administered subcutaneously) and 
DPP4 inhibitors (administered orally). There are of great scientific interest to treat type II 
diabetes in human patients. The first DPP4 inhibitor was developed and tested in the late 1990s in 
animal models. According to the literature, isoleucine thiazolidide, vildagliptin, NVP-DPP728 
and valine-pyrrolidide were used to inhibit DPP4, mainly in rodents. These agents improved 
glucose tolerance, induced greater levels of GLP-1(7-36), reduced body weight gain, potentiated 
the plasma insulin response to intra-gastric glucose and increased hepatic and peripheral insulin 
sensitivity (Flatt et al., 2008). 
In clinical development the inhibitors have received the class name of “gliptins” or “incretin 
enhancers”. The first DPP4 inhibitor for clinical use to treat type II diabetes was sitagliptin, 
which was launched in Mexico in 2006 and in the United States and Germany in 2007 (Flatt et 
al., 2008). Today, vildagliptin, saxagliptin and alogliptin are further DPP4 inhibitors but are still 
under development. A multitude of studies demonstrates positive, anti-diabetic effects with 
enhanced postprandial and fasting glycemic control, as well as a possible improvement and 
preservation of the β-cell function and mass (Neumiller, 2009). The named inhibitors provide a 
selective and nearly complete inhibition of DPP4 for >12 h (Flatt et al., 2008).  
Because type II diabetes is also known as a low grade systemic inflammatory disease, especially 
in patients with metabolic syndrome and/or atherosclerosis, studies focused more and more on 
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the anti-inflammatory effects of DPP4 inhibitors. These results are contradicting. Due to the 
inhibition of DPP4, the production of proinflammatory cytokines (e.g. IL-1 β, IL-6, IL-8, TNF-α) 
is reduced, in vitro and in vivo (Rizzo et al., 2012; Ta et al., 2011). In contrast, Anz et al. (2014) 
found no influence of sitaglipitin, saxagliptin and vildagliptin on the immune response in terms 
of cytokine production (IL-6, IL-10, IL-12, interferon-γ), co-stimulation (e.g. molecules of major 
histocompatibility complex class II) and T-cell proliferation or migration.  
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2. Scope of the thesis 
Taking the background information into consideration, DPP4 is a key enzyme in intermediary 
metabolism by regulating important glycemic pathways. At the same time DPP4 shows immune 
modulatory characteristics, especially at a cellular level. The ketotic metabolic status of high 
yielding dairy cows during early lactation exhibits parallels with the metabolic situation in human 
patients with type II diabetes and fatty liver. Therefore, DPP4 inhibitors might counteract typical 
ketotic processes in the dairy cow. In the present research and in cooperation with Boehringer 
Ingelheim, a DPP4 inhibitor (BI 14332) was tested for its effects on bovine ketosis. The 
experimental trail was conducted to induce an artificial ketotic status in Holstein Friesian cows 
for treating them subsequently with the named DPP4 inhibitor. 
 Overfeeding in the dry period and a reduced feed intake p.p. result in a distinct NEB 
and an excessively stimulated lipomobilisation. With the onset of lactation, cows will 
enter a ketotic metabolic status, characterized by BHB concentrations in blood serum 
≥1.2 mM (Paper I). 
 The ketotic metabolism, in particular BHB as most important component, causes 
immune-modulatory alterations (Paper II). 
 The treatment of bovine ketosis by BI 14332 adjusts elevated variables of the fatty 
liver syndrome and ketosis to the physiological range. In consequence hepatic 
lipidosis is reduced (Paper III). 
 The inhibition of DPP4 via BI 14332 protects against inflammatory processes and 
influences the immune response (Paper III). 
To investigate the effects of DPP4 inhibition via BI 14332 during ketosis, first the induction of a 
ketotic status was necessary, realized by a feeding trial with 30 primi- and multiparous cows. The 
experimental period started six weeks before the expected parturition until the 56
th
 day in milk. 
With first occurrence of serum BHB ≥ 1.2 mM, BI 14332 was administered (intravenously, daily, 
for 7 days).  
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3. Paper I (Published in Journal of Dairy Research, 2014, 81:257-266) 
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Abstract 
Subclinical ketosis is a metabolic disorder which often goes undiagnosed and leads to constricted 
performance and an impairment of the general condition. In the current study subclinical ketosis 
was characterized by a β-hydroxybutyrate (BHB) concentration of > 1.2 mmol/l in blood serum. 
To generate this metabolic situation, an animal model was created. The model, based on group-
specific interaction of dietary energy supply and body condition, is appropriate for testing 
medical effectiveness to treat this kind of ketosis and its concomitants. During the trial, 18 dairy 
cows (primiparous and pluriparous) were assigned, according to their body condition score 
(BCS) 6 weeks before expected parturition, to a normal [6.78 MJ net energy for lactation 
(NEL)/kg dry matter; 20% concentrate] and a high-energy feeding group (7.71 MJ NEL/kg dry 
matter; 60% concentrate). Therefore cows with the highest BCS were allocated to the high-
energy group to enhance the contrast to the control group. Statistical analysis was done using the 
MIXED procedure of SAS. Effects were declared significant when P-values were ≤ 0.05. Owing 
to the higher energy concentration and dry matter intake, the energy intake and balance was 
significantly higher in the high-energy feeding group, with strong effects on lipid metabolism and 
health in blood and liver post partum. Within the first 2 weeks after calving, 8 out of 9 cows (89 
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%) of the high-energy group had BHB values indicative of subclinical ketosis. These cows also 
had significantly higher values of non-esterified fatty acids (NEFA), aspartate transaminase 
(AST) and glutamate dehydrogenase (GLDH) post partum, as well as a raised total lipid content 
of the liver. RQUICKI, a calculated parameter which is based on serum concentrations of 
glucose, insulin and NEFA to assess the insulin sensitivity, was not affected by treatment. 
Therefore, RQUICKI does not seem to be the right parameter for diagnosing decreased insulin 
sensitivity in cows affected by subclinical ketosis. The milk fat and the fat:protein ratio of the 
high-energy group was also higher, even though there was no decrease in milk yield for cows 
with subclinical BHB values. 
Keywords: Animal model, dairy cow, body condition score, subclinical ketosis, hepatic lipidosis, 
energy balance. 
Introduction 
It is well established that in early lactation, the available metabolisable energy (ME) from dry 
matter intake (DMI) is not sufficient to satisfy the energy requirements of the dairy cow. The 
required energy for milk (EL) and maintenance (EM) cannot be covered only by feed intake alone 
(Bauman & Currie, 1980). Owing to early lactation energy balance, the dairy cow mobilises 
energy from body mass (mainly fat reserves), resulting in increased lipolysis. Differences from 8-
56 kg of body fat mobilisation were observed in Dutch and Holstein Frisian cows during the first 
8 weeks after calving (Tamminga et al., 1997). Such a strong fat mobilization induces an 
imbalance of the fat- and carbohydrate metabolism with a typical increase of ketone bodies and 
the possibility for its manifestation as subclinical or clinical ketosis. According to the literature, 
studies using BHB to define a subclinical ketosis, report ranges of values from 1.0 mmol/L to 1.4 
mmol/l as threshold (Duffield, 2000). Dirksen et al. (2012) summarised the literature and defined 
a level of < 1.2 mmol BHB in blood serum as physiological, characterized by a balanced energy 
supply. So ketogenesis during early lactation, produced in a range of < 1.2 mmol/l BHB is a 
considerable metabolic pathway to compensate the insufficient intake of glucose precursors, 
while increasing concentrations up to 3 mmol/l are defined as subclinical ketosis (Dirksen et al., 
2012; Duffield, 2000). Recently, an average incidence of subclinical ketosis of 43% was reported, 
with a peak incidence 5 d after calving (McArt et al., 2012). 
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In addition, ketosis is associated with hepatic lipidosis. The extent of the negative energy balance 
(NEB) and the body condition during dry period determine the potential development of a fatty 
liver, which results as an increased hepatic uptake of non-esterified fatty acids (NEFA) from 
blood. The NEFAs are mobilized from adipose tissue, in an amount greater than needed, so that 
the excess is transported to the liver (Bobe et al., 2004), inducing a fatty liver with an impairment 
of the general condition in dairy cattle. In particular the body condition score (BCS) is still an 
object of research for the prevention of excessive negative metabolic changes in dairy cows, as it 
is a parameter which shows good correlation with increased risk of fatty liver or ketosis 
(Bernabucci et al., 2005; Bewley & Schutz, 2008; Roche et al., 2013).  
Current publications describe the changes in blood profile in regard to ketosis and hepatic 
lipidosis over a defined period around calving (Asl et al., 2011; Gonzalez et al., 2011; Stengarde 
et al., 2011). Next to this, in Europe, a monensin slow-release bolus was recently permitted as a 
ketosis prophylactic measure which hints at the practical relevance of this disease (Day, 2013). 
The current literature and the continuing interest in metabolic changes during early lactation, 
underline the usefulness of the present work.  
The object of the study was to create an animal model which induces BHB values indicative for 
subclinical ketosis (BHB in blood > 1.2 mmol/l) due to a heightened lipomobilisation, and to 
monitor how this physiological condition affects bovine metabolism. We hypothesize that the 
combination of overfeeding in the dry period and a reduced feed intake post partum will result in 
a NEB that will cause ketosis. With the model the relationship between blood profile and 
metabolic diseases can be elucidated, with the possibility of showing pharmacological effects to 
medicate subclinical ketosis and the fatty liver syndrome. The continued productivity of high-
yielding dairy cows and the still existing clinical picture of ketosis, especially with regard to 
pluriparous cows during transition period, account for the importance of prophylaxis and therapy. 
Materials and methods 
Experimental design 
The experiment was carried out at the experimental station of the Institute of Animal Nutrition, 
Friedrich-Loeffler-Institute (FLI) in Braunschweig, Germany. In the study 18 pregnant and 
healthy German Holstein cows, 10 pluriparous and 8 primiparous, were selected according to 
BCS (Edmonson et al., 1989), using a 5-point scale. Nine cows (5 pluriparous, 4 primiparous) 
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with a BCS of 2.61 ± 0.09 were selected to a normal condition group (NC), acting as a control 
group, and 9 cows (5 pluriparous, 4 primiparous) with a BCS of 3.19 ± 0.09 were selected to the 
experimental group, called higher condition group (HC). To enhance the contrast between 
control- and experimental group, the cows with the highest BCS were allocated to the 
experimental group. The BCS at the time of classification between these two groups was 
statistically different (P < 0.01) and was then established weekly. The experimental period started 
6 weeks before expected parturition and continued until the 56
th
 day after calving. 
Table 1. Ingredients and chemical composition of concentrate and total 
mixed ration of the pre-partum diet 
  Concentrate TMR
† 
Ingredients, %   
 Wheat           41.0  
 Dried sugar beet pulp 30.5  
 Rapeseed meal 20.0  
 Soybean meal 6.5  
 Vitamin/mineral premix
§
 2.0  
  HC
‡
 NC
‡
 
Dry matter (DM), g/kg 877 489 384 
Nutrients [g/kg DM]    
 Crude ash 58 55 51 
 Crude protein 197 140 117 
 Ether extract 27 33 35 
 Crude fibre 101 163 201 
 Acid detergent fibre (ADF) 136 199 231 
 Neutral detergent fibre (NDF) 279 394 429 
Energy
¶
, MJ NEL/kg DM 8.6 7.7 6.8 
†
Total mixed ration on DM basis (75% corn silage, 25% grass silage on DM basis) 
§
High condition (HC) cows were fed a concentrate proportion of 60% in the diet; Normal 
condition (NC) cows were fed a concentrate proportion of 20% in the diet 
‡
Per kg of mineral feed: 10g Ca, 60g P, 120g Na, 60g Mg, 800,000 IU vitamin A, 100,000 
IU vitamin D3, 2500mg vitamin E, 4000mg Mn, 6000 mg Zn, 1250mg Cu, 100mg I, 35mg 
Co, 50mg Se 
¶
Calculation based on nutrient digestibilities masured with wethers (GfE, 1991) and values 
from feed tables (DLG, 1997) 
Prepartum, the cows of NC group were fed with an energetically adequate ration, based on the 
recommendations of the German Society of Nutrition Physiology (GfE, 2001), of 80% roughage 
(75% corn silage and 25% grass silage based on DM content) and 20% concentrate, whereas the 
cows of HC group where fed a ration, consisting of 40% roughage and 60% concentrate which 
led to an energetic oversupply (Table 1). After calving, all animals were initially fed with a 
standardized TMR for lactation, consisting of 30% concentrate. The ingredients and chemical 
composition for the lactation TMR are given in Table 2. Immediately after calving, the 
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concentrate proportion was raised stepwise, applied by a computerized feeding station (Insentec, 
B.V., 1274 Marknesse, The Netherlands), from 30% to 50% within the first 2 or 3 weeks for NC 
or HC group, respectively. The initialized increase occurred more slowly in the HC group (Figure 
1), with the additional aim to stimulate postpartal lipolysis. Cows were fed ad libitum and had 
free access to water. 
Table 2. Ingredients and chemical composition of concentrate and total 
mixed ration during lactation period 
 Concentrate TMR
† 
Ingredients (%)   
 Wheat           41.0  
 Dried sugar beet pulp 30.3  
 Rapeseed meal 20.0  
 Soybean meal 6.5  
 Vitamin/mineral premix
‡ 
2.0  
 Calcium carbonate  0.2  
Dry matter [g/kg] 875 393 
Nutrients [g/kg DM]   
 Crude ash 62 56 
 Crude protein 202 122 
 Ether extract 28 32 
 Crude fibre 72 194 
 Acid detergent fibre (ADF) 96 222 
 Neutral detergent fibre (NDF) 222 431 
Energy
§
 [MJ NEL/kg DM] 8.7 7.0 
†
Total mixed ration on DM basis (70% roughage (75% corn silage, 25% grass silage) + 
30% concentrate) 
‡
Per kg of mineral feed: 170g Ca, 50g P, 120g Na, 45g Mg, 800,000 IU vitamin A, 
100,000 IU vitamin D3, 4000mg vitamin E, 4000mg Mn, 6000mg Zn, 1300mg Cu, 120mg 
I, 35mg Co, 40mg Se 
§
Calculation based on nutrient digestibilities masured with wethers (GfE, 1991) and 
values from feed tables (DLG, 1997) 
The classification of a cow as healthy, subclinical ketotic or clinic ketotic was based on the 
concentration of BHB in blood serum. Therefore, BHB values between 1.2 – 2.5 mmol/l were 
characterized as a subclinical metabolic status, lower values meant a healthy animal, whereas 
higher values indicated clinical ketosis.   
Sample Preparation and Measurement 
The daily individual feed intake was recorded for the whole experimental time (computerized 
feeding station: Type RIC, Insentec, B.V., 1274 Marknesse, The Netherlands). Representative 
concentrate samples were taken once, grass and maize silage twice a week, while TMR samples 
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were collected daily and pooled monthly. Feedstuffs were analyzed for dry matter (DM), crude 
protein (CP), crude ash (CA), ether extract (EE), crude fibre (CF), neutral detergent fibre (NDF) 
and acid detergent fibre (ADF), according to the guidelines of the Association of German 
Agricultural Analytic and Research Institute (VDLUFA, 1993). 
  
Fig. 1. Concentrate proportion of the diet (%) of high (HC) and normal (NC) condition groups during 
experiment. 
Milking took place twice a day at 05.30 and 15.30. Milk yield was recorded using automatic milk 
counters (Lemmer Fullwood GmbH, 53797 Lohmar, Germany) and body weight was always 
determined when leaving the milking parlor. Milk samples were taken twice a week and stored at 
4°C for analyzing fat, protein, lactose and urea concentration, using infrared milk analyzer 
(Milkoscan FT 6000 in combination with a Fossomatic 5000; Foss Electric, 3400 Hillerød, 
Denmark). 
At day -48 (control sample; 48 ± 7.19 days antepartum), -14, -7, -3, 1, 3, 7, 10, 14, 17, 21, 24, 28, 
35, 42 and 56 (relative to calving) blood samples for clinical-chemical parameters were taken 
from the vena jugularis. Immediately after centrifugation (Heraeus Varifuge® 3.0R, 2000g, 
15°C; 15 minutes) serum concentrations of BHB, NEFA, glucose and triglycerides (TG) were 
measured using an automatic analyzing system, based on a photometric measurement (Eurolyser, 
Type VET CCA, 5020 Salzburg, Austria). Serum concentration of total protein, albumin, 
cholesterol, urea, aspartate-aminotransferase (AST), γ-glutamyl transferase (γ-GT) and glutamate 
dehydrogenase (GLDH) were measured the same way. The concentration of insulin was analyzed 
by the endocrinology laboratory of the Cattle Clinic (University of Veterinary Medicine, 30173 
Hanover, Germany) using radioimmunoassay (RIA). Samples were stored at -80°C interim.  
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Liver samples were taken on day -14, 7, 21, 35 and 56 (relative to calving). Therefore 
approximately 200 mg of tissue were removed from bovine liver by minimally invasive, 
transcutaneous cutting biopsy needle technique under local anesthesia. The acquired liver tissue 
was analyzed for the content of total lipid (TL). The gravimetrical method used, based on the 
publication by Starke et al. (2010). For the determination in milligrams per gram of fresh liver 
weight, the TL was extracted from homogenized tissue samples with hexane:isopropanol (mixing 
ratio 3:2, continual agitation, 20°C, 24h). 
Calculations 
The net energy lactation (NEL) of concentrates was calculated by using the nutrient digestibility 
from studies with wethers according to GfE (1991), whereas the data for corn- and grass silage 
are based on feed tables (DLG, 1997). According to formulas published by GfE (2001), the 
requirement for maintenance (EM), milk production (EL) and the energy balance were calculated 
as follows: 
Maintenance requirement:  
Energy content of milk:  
Requirement for milk production: 
 
4% Fat-corrected milk (FCM) was calculated based on the equation of Gaines (1928): 
 
Calculation of the energy balance as follows: 
 
Before calving, the energy balance was calculated by subtracting the requirement of maintenance 
and for pregnancy (GfE 2001) from daily net energy intake. During the last 6 weeks of gestation 
13 MJ NEL/d are required in addition, with an increase to 18 MJ NEL/d for the last 3 weeks.  
In particular to the insulin sensitivity, the Revised Quantitative Insulin Sensitivity Check Index 
(RQUICKI) was calculated by Holtenius and Holtenius (2007): 
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Statistical Analysis 
For the statistical analysis, the whole trial period became classified into three time periods. Period 
1 describes the time prepartum and summarized the days -48, -14, -7 and -3. Period 2 centralizes 
the first 2 weeks post partum (including days 1, 3, 7, 10 and 14), while in Period 3 the time points 
from the lactation week 3 (day 17, 21, 24, 28, 35, 42 and 56) are summarized. According to this 
classification all parameters of the performance and the clinical chemistry were evaluated. 
All statistics were performed by using the MIXED procedure of SAS (Software package, Version 
9.1, SAS Institute, 2004). Effects were declared significant when P-values were ≤ 0.05 after 
Tukey test. Each parameter was analyzed by a compound symmetry covariance structure. For 
clinical-chemical parameters the model contained feeding group and period, including the 
interaction between the factors. The performance was evaluated similarly, but in consideration of 
the parity as additional fixed factor. All results are represented at least square means (LSmeans) 
and standard error of the mean (SEM). 
 
Fig. 2. Total lipid (TL) content of the liver of high (HC) and normal (NC) condition group at sampling 
points during experiment (
†
6 weeks before expected parturition). Values are LSMeans ± SEM; *P ≤ 0.01. 
Results 
Over the entire trial, six out of nine cows of the high condition (HC) group developed a 
subclinical form of ketosis (BHB in blood serum > 1.2 mmol/l), two cows had BHB values 
indicative for clinical ketosis (BHB > 2.5 mmol/l) and one cow remained healthy. The two cows 
with clinical ketosis had the highest BHB values with 4.39 mmol/l and 2.92 mmol/l on day 7 and 
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10 after calving, respectively. In the normal condition (NC) group eight out of nine animals 
stayed healthy. The diseased cow had the same indicative serum concentrations like the 
subclinical ketotic cows in HC group. All 13 parameters of the clinical chemistry, including 
RQUICKI, are shown for both feeding groups in Table 3. Insulin and urea levels are significantly 
higher in HC group in Period 1 (P < 0.0001). Serum concentrations of BHB and NEFA differ 
significantly among the groups in Period 2, as does AST. In the 3rd period, the urea level is 
significantly higher and the GLDH level significantly lower in NC vs. HC cows. The TL content 
of the liver is also shown in Table 3, with high significant intergroup differences in both periods 
post partum (P < 0.01). A graphical presentation for the evaluated days of experiment is given in 
Figure 2. There is a significant difference between both groups on day +7 (154.06 mg/g in HC vs. 
69.23 mg/g in NC) and day +21 (132.33 mg/g in HC vs. 69.83 mg/g in NC). Detailed evaluations 
of BHB and NEFA for the single time points are shown in Figure 3, with a significant difference 
after calving. 
 
 
Fig. 3. Values of beta-hydroxy butyrate (BHB) and non-esterified fatty acids (NEFA) in blood serum of 
high (HC) and normal (NC) condition group at sampling points during experiment. Values are LSMeans ± 
SEM; *P < 0.05; **P < 0.01. 
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Changes of BCS in the two groups are demonstrated in Figure 4. At the time of classification (6 
weeks before expected parturition), the difference in BCS between HC and NC was significant (P 
< 0.01). During the further course of the experiment, the BCS showed significant differences 
with regard to the group (P < 0.0001) and the lactation week (P = 0.0052), even though the 
interaction of group and lactation week was not significantly affected (P = 0.820; data not 
shown). The first marked increase (although the increase was found to be not significant) took 
place 4 weeks post partum for both groups (Figure 4).  
 
Fig. 4. Comparison of the body condition score (BCS) of high (HC) and normal (NC) condition groups 
during the experiment (†6 weeks before expected parturition). LSMeans ± SEM; *P < 0.01.  
The results for the performance parameters are given in Table 4. Based on the individual feed 
intake prepartum, there is a high significant difference (P < 0.01) between groups for DMI, net 
energy intake and energy balance in Period 1. Figure 5 shows the energy balance for every single 
week of the experimental time with a significant difference between HC and NC 3 weeks before 
calving (P = 0.0046). In addition, the NC cows overcome their negative energy balance post 
partum faster than the HC animals, namely in week 7 of lactation. 
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Table 3. Blood serum parameters of the clinical chemistry and the total lipid content of the liver of high (HC) and normal (NC) condition 
group within Period 1 (6 weeks before expected parturition till calving), Period 2 (first 2 weeks postpartum) and Period 3 (2
nd
 week – 8th 
week postpartum) (LSMeans ± SEM). 
 Period 1 Period 2 Period 3 
 Treatment
†
  Treatment
† 
 Treatment
† 
 
 HC NC P-value HC NC P-value HC NC P-value 
BHB, mmol/l
‡
   0.64 ± 0.09    0.63 ± 0.09 1.000     1.30 ± 0.08     0.78 ± 0.08   0.0002     0.89 ± 0.08     0.81 ± 0.08 0.981 
NEFA, mmol/l   0.28 ± 0.05    0.37 ± 0.05 0.812     0.88 ± 0.04     0.58 ± 0.04 < 0.0001     0.52 ± 0.04     0.38 ± 0.04 0.132 
Glucose, mg/dl 68.61 ± 2.91  66.82 ± 3.04 0.998   67.92 ± 2.60   64.12 ± 2.53 0.900   62.97 ± 2.25   63.07 ± 2.24 1.000 
Triglyceride, mg/dL 21.07 ± 0.77  21.55 ± 0.79 0.998   12.41 ± 0.69   10.43 ± 0.67 0.308   11.28 ± 0.59   11.05 ± 0.58 1.000 
Albumin, g/L 32.72 ± 0.80  30.99 ± 0.82 0.659   34.69 ± 0.76   32.11 ± 0.75 0.153   34.33 ± 0.71   34.18 ± 0.71 1.000 
Total protein, g/L 66.17 ± 1.73  63.99 ± 1.75 0.950   71.22 ± 1.64   68.08 ± 1.61 0.749   72.23 ± 1.54   73.02 ± 1.53 0.999 
Cholesterol, mg/dL 92.29 ± 7.55  92.14 ± 7.65 1.000   78.20 ± 7.20   82.82 ± 7,12 0.998 142.89 ± 6.83 129.34 ± 6.81 0.724 
Urea, mg/dL 22.53 ± 0.92  14.88 ± 0.94 < 0.0001   18.11 ± 0.82   15.53 ± 0.80 0.215   15.57 ± 0.69   18.72 ± 0.69   0.0181 
γ-GT, U/L 17.04 ± 3.22  16.24 ± 3.28 1.000   20.20 ± 3.04   19.99 ± 2.99 1.000   31.28 ± 2.85   22.31 ± 2.83 0.226 
AST, U/L 54.78 ± 5.21  49.40 ± 5.30 0.979   97.11 ± 4.92   73.01 ± 4.85   0.0075   81.21 ± 4.57   65.82 ± 4.56 0.165 
GLDH, U/L   6.63 ± 2.52    7.04 ± 2.57 1.000   11.17 ± 2.43     9.39 ± 2.37 0.995   26.73 ± 2.18   15.20 ± 2.17   0.0030 
Insulin, mU/mL 30.32 ± 2.01  16.74 ± 2.06 < 0.0001     7.02 ± 1.87   10.43 ± 1.83 0.888   12.97 ± 1.70   14.56 ± 1.70 0.999 
RQUICKI
¶
   0.38 ± 0.01    0.41 ± 0.01 0.172     0.42 ± 0.01     0.42 ± 0.01 1.000     0.41 ± 0.01     0.42 ± 0.01 0.897 
TL in liver, mg/g 43.26 ±12.02  48.13 ± 12.75 0.999 154.06 ± 12.02   69.23 ± 12.75   0.0001 110.45 ± 8.97   62.04 ± 9.52   0.0058 
†
Treatments: High condition (HC) cows were fed a concentrate proportion of 60% during Period 1, after calving the proportion raised from 30 to 42% (Period 2) till 
50% (Period 3). Normal condition (NC) cows were fed a concentrate proportion of 20% during Period 1, which was raised from 30 to 50% in Period 2 and stayed at 
50% during Period 3. 
‡
BHB, β-hydroxybutyrate; NEFA, non-esterified fatty acids; γ-GT, γ-glutamyltransferase; AST, aspartate aminotransferase; GLDH, glutamate dehydrogenase; TL, 
total lipid 
¶
Revised quick insulin sensitivity index, calculated by Holtenius and Holtenius (2007) 
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Table 4. Performance, milk composition and energetic variables of high (HC) and normal (NC) condition group within Period 1 (6 
weeks before expected parturition till calving), Period 2 (first 2 weeks postpartum) and Period 3 (2
nd
 week – 8th week postpartum) 
(LSMeans ± SEM). 
 Period 1 Period 2 Period 3 
 Treatment
†
  Treatment
†
  Treatment
†
  
 HC NC P-value HC NC P-value HC NC P-value 
DMI, kg/d   15.8 ± 0.6   12.5 ± 0.6 0.0019   12.0 ± 0.71     13.7 ± 0.7 0.533    18.1 ± 0.6   18.7 ± 0.6 0.960 
Net energy intake, MJ/d 124.1 ± 4.2   84.2 ± 4.1 0.0000   83.9 ± 5.2     95.8 ± 5.2 0.585  126.1 ± 4.1 131.1 ± 4.1 0.974 
Live weight, kg    708 ± 15    679 ± 14 0.773    586 ± 15      562 ± 15 0.872     589 ± 14    595 ± 14 0.999 
Energy balance, MJ NEL/d   61.9 ± 7.3   26.2 ± 6.7 0.0141    -6.1 ± 7.8     17.3 ± 7.8 0.305   -22.1 ± 6.3    -0.2 ± 6.3 0.172 
Body condition score   3.18 ± 0.10   2.79 ± 0.09 0.0656   2.94 ± 0.10     2.59 ± 0.10 0.194    2.92 ± 0.09   2.77 ± 0.09 0.882 
Milk yield, kg/d      27.6 ± 1.2     26.2 ± 1.2 0.849    34.0 ± 1.1   29.6 ± 1.1 0.0316 
Milk fat, %      6.04 ± 0.31     4.33 ± 0.31 0.0010    4.33 ± 0.24   4.03 ± 0.24 0.816 
Milk fat, kg/d      1.68 ± 0.12     1.16 ± 0.12 0.0216    1.55 ± 0.10   1.24 ± 0.10 0.146 
FCM
‡
, kg/d      36.7 ± 1.9     29.0 ± 1.9 0.0234    35.4 ± 1.8   29.7 ± 1.8 0.108 
Milk protein, %      3.43 ± 0.08     3.51 ± 0.08 0.882    3.23 ± 0.05   3.29 ± 0.05 0.826 
Milk protein, kg/d      1.07 ± 0.10     1.10 ± 0.10 0.994    1.16 ± 0.08   1.06 ± 0.08 0.807 
Milk lactose, %      4.76 ± 0.11     4.93 ± 0.11 0.655    5.00 ± 0.08   5.08 ± 0.08 0.896 
Milk lactose, kg/d      1.35 ± 0.08     1.72 ± 0.06 0.918    1.28 ± 0.08   1.52 ± 0.06 0.137 
Fat:protein ratio in milk      1.76 ± 0.10     1.25 ± 0.10 0.0018    1.35 ± 0.07   1.23 ± 0.07 0.691 
†
Treatments: High condition (HC) cows were fed a concentrate proportion of 60% during Period 1, after calving the proportion raised from 30 to 42% (Period 2) 
till 50% (Period 3). Normal condition (NC) cows were fed a concentrate proportion of 20% during Period 1, which raised from 30 to 50% in Period 2 and stayed at 
50% during Period 3. 
‡
4% fat-corrected milk 
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Fig. 5. Energy balance of high (HC) and normal (NC) condition groups during the experiment. Values are 
LSMeans ± SEM; *P ≤ 0.01. 
A high statistical relevance is also shown in the 2
nd
 period in regard to milk fat, absolute as well 
as relative (Table 4). Due to the higher milk fat content in HC group, also the parameters FCM 
and FPR (fat:protein ratio of the milk) clarify a significantly higher level compared to the NC 
feeding group. In Period 3 the milk yield differs significantly between the two groups. Thereby 
the average milk production of the HC group is 4.35 kg per day higher than the production within 
the NC group. There are no more differences observed in Period 3. 
Discussion 
Our animal model to investigate subclinical ketosis was based on a factorial design with three 
important factors: The BSC 6 weeks before expected parturition and the subsequent classification 
to high and normal condition, the group-individual DM and energy intake prepartum, as well as 
the initialized increase in energy input till the week 3 after calving. Bobe et al. (2004) reviewed 
that studies that investigate the effects of BCS, prepartal and postpartal diet in a factorial design 
are warranted. Due to the model, the changed physiological situation of HC cows could be 
compared to the healthy NC cows.   
Bewley and Schutz (2008) reviewed that fat cows tend to lose more body condition during early 
lactation than thin cows. As the present study based on a group-specific feeding management, 
these data are difficult to compare. Due to the accelerate proportion of concentrate for the NC 
cows during the first 2 weeks after calving, the differences in BCS post partum between NC and 
HC become less pronounced. Nevertheless, BCS at calving represents an important risk factor for 
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subsequent development of subclinical ketosis during lactation (Duffield, 2000). In the present 
study 6 out of 9 cows of the HC group developed subclinical ketosis. These 6 cows had an 
average BCS of 3.50 one week before calving. In the NC group 8 out of 9 cows stayed healthy 
and had an average BCS of 2.90 one week before calving, which was significantly different to the 
BCS of HC cows with subclinical ketosis at that time (P = 0.016; data not shown). This 
difference in BCS endorsed the success of our animal model, as the artificial provoked 
subclinical ketosis is a result of a higher BCS combined with experimental feeding management 
ante- and post partum.  
Owing to the feeding management in the animal model, DMI was higher in the HC group 
prepartum and higher in the NC group post partum. It was not clear whether or not the energy 
balance for the time prepartum could be calculated according to the formulas published by GfE 
(2001). The high proportion of concentrate in HC group during dry period came along with 41% 
wheat, which is highly degradable in the rumen, and a low crude fibre content (16.3%). So the 
authors cannot exclude the possible development of an at least mild acidosis. In this situation a 
reduced digestion of the ingredients is possible (Owens et al., 1998). Despite this, the energy 
balance was significantly higher in HC cows within the experimental dry period. Additionally, 
NC cows were able to compensate their NEB faster (Figure 5). This was partly due to the faster 
increase of energy for NC cows post partum and partly to the lower milk yield in Period 3 (Table 
4). These results are comparable to other studies (Holcomb et al., 2001; Vickers et al., 2013). In 
addition, the various nutrient and energy intake prepartum was also reflected by the significant 
different serum blood concentrations of urea and insulin in Period 1 (Table 3), caused by the 
higher concentration of crude protein and energy in HC feedingstuff. 
Regarding the milk parameters, significant differences in our results were typical for subclinical 
ketosis and confirm other findings (Miettinen & Setälä, 1993; Duffield, 2000; LeBlanc, 2010). 
According to the literature, the milk yield is significantly decreased in almost every case of 
ketosis, even subclinical ketosis (Duffield, 2000). For the present study this did not apply. In the 
HC group, where 89% had BHB values indicative for clinical or subclinical ketosis, the milk 
yield was significantly higher during Period 3 (Δ = 4.35 kg/d). The milk yield was also higher in 
Period 2 (Δ = 1.4 kg/d), even if this difference was not statistically relevant. A few studies with 
similar results were found. The comparison of healthy and subclinically ketotic cows show 
continuously higher milk yields until the 6th week of lactation in the group of subclinical cows 
(Asl et al., 2011). In comparison of cows with lower (≤ 3.25) and higher BCS (> 3.25), the 
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average milk yield is numerically higher for the fatter ones (Busato et al., 2002). Quite in line 
with this, Domecq et al. (1997) found, in a study with 779 cows, that a one-point increase 
(Edmonson-scale) between dry-off and parturition is associated with 546 kg more milk in the first 
120 days of lactation. Based on our data and consistent with these findings, cows with a higher 
BCS at calving tended to yield more milk. We suggest that our HC cows, which underwent a 
slower energy adaption during the first 3 weeks post partum, used the mobilized body mass as an 
energy source for milk production, even if the same cows had BHB values indicative of clinical 
or subclinical ketosis. That a fat body condition is related to a higher milk yield is also described 
by Heuer et al. (1999). They equate the higher milk production with a FPR > 1.5, which 
coincides with high lipolysis and an elevated risk for ketosis (Heuer et al., 1999; Buttchereit et 
al., 2010). Consistent with those studies, we found a FPR of 1.76 in HC group during Period 2 
which was significantly different from the FPR of NC cows during Period 2 (Table 4).  
According to the serum parameters, bovine subclinical ketosis in combination with high 
lipomobilisation can be diagnosed if the following values are on par: BHB > 1.2 mmol/l, glucose 
< 2.5 mmol/l, TG < 0.08 mmol/l and NEFA > 0.4 mmol/l (Oetzel, 2004; Gonzalez et al., 2011; 
Dirksen et al., 2012). This combination applied to eight out of nine cows from the HC group, in 
which all eight cows had BHB values indicative for clinical or subclinical ketosis during the 
ongoing trial.  
Our results show that the ketotic metabolic status strongly affected liver metabolism, reflected by 
the difference of the TL content pre- and post partum (Table 3 & Figure 2). Normally the TL 
content of the liver alone allows no adequate inference to classify a fatty liver. Nevertheless a TL 
content of 3 - 6% is considered as physiological and should be in this range for the time 
prepartum and from the 8th week after calving (Fürll, 1989). Ametaj et al. (2005) established 
cows with a TL content more than 10% as cows with fatty liver. In the present paper, within the 
HC group, a content of 15.4% and 11% TL were measured during Period 2 and 3. Depending on 
the available literature, such a concentration of TL can be classified as mild fatty infiltration, 
which is almost physiological (Đokovic´ et al., 2012). Due to the infiltration of fat, lesions in 
hepatic tissues appear and cause increased blood levels of specific enzymes (Bobe et al., 2004). 
Gonzalez et al. (2011) describe an AST level of higher than 100 U/L as indicative for hepatic 
lesions. In our case, seven out of nine cows from the HC group (77.8%) showed AST 
concentrations higher than 100 U/L during early lactation. These seven cows also included the 
two clinically ketotic animals (BHB > 2.5 mmol/l; AST maximum of 219.44 U/L) and not the 
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one who stayed healthy (AST maximum of 81.83 U/L). The seven cows together offered an 
average TL content of 17% and 15% for the days 7 and 21, relative to calving (data not shown). 
Next to AST, GLDH is useful for analyzing longer acting influences, so that a variation of the 
activity occurs about 3 to 5 weeks after the impacts. This fact is verified by the high level of 
GLDH, exceeding the physiological level of 10 U/L (Dirksen et al., 2012) and the significant 
difference between the feeding groups in Period 3 (Table 3). In summary, even a liver lipid 
content of about 15% can be classified as mild to moderate fatty liver if further parameters like 
AST show increased levels, far beyond their physiological range. However, it has to be supposed 
that the fatty degeneration was reversible, because the TL values and serum concentrations of 
AST, BHB and NEFA decreased and normalized towards the end of the trial. 
An insulin resistance is present, when higher than normal insulin concentrations are needed to 
achieve normal metabolic responses and has already been demonstrated in case of hepatic 
lipidosis of dairy cattle (Oikawa & Oetzel, 2006). Holtenius and Holtenius (2007) consider, that 
different kinds of glucose tolerance tests for clinical investigations are too time-consuming and 
not suitable for cows. They assess insulin sensitivity on the basis of RQUICKI, and found that 
this calculated parameter might be useful to identify a disturbed insulin function in cows. In our 
study, post partum RQUICKI was lowest on day +1 (data not shown) for both groups. However, 
there is no significant difference between groups to any point of time (Table 3) and consequently 
no relationship between RQUICKI and subclinical ketosis. These results are contrary to 
Stengarde et al. (2011), who describe RQUICKI as a more sensitive parameter for metabolic 
imbalances than separate evaluation of glucose, insulin and NEFA. However, the respective 
serum values in the present study were substantially higher. For example the serum NEFA and 
BHB levels in HC group during Period 2 are nearly twice as high compared to Stengarde et al. 
(2011). This induced a pathological metabolic situation and confirms the statement, that 
RQUICKI has a low discrimination power in diagnosing decreased insulin sensitivity in cows 
affected by a metabolic disease (Kerestes et al., 2009).  
In conclusion, we give an example of how the physiological situation of subclinical ketosis 
affects the whole bovine metabolism. Therefore, the prerequisite was the development of an 
animal model that induces exactly such a metabolic situation. The described animal model based 
on a combination of three different influencing factors: First, the overfeeding in the dry period; 
second the decelerated energy supply with concentrate in the first 3 weeks of lactation and at last, 
the grouping of cows with a higher BCS 6 weeks before expected parturition to the experimental 
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group to enhance the contrast compared to the animals of the control group. We confirm that the 
combination of the named factors cause the success of our investigation. We summarize, that the 
cows of experimental group developed a subclinical ketosis in the time of early lactation and 
provide the opportunity to investigate metabolic interrelations of subclinical ketosis, as well as an 
appropriate model for testing medical effectiveness to treat ketosis and fatty liver syndrome. 
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Abstract 
Using an established model in which subclinical ketosis is induced, the response of differential 
blood counts and levels of various haematological variables, including the inflammatory marker 
haptoglobin (Hp), were tested over the last 6 weeks of parturition until the 56
th
 day post-partum 
in cows with lower or higher body condition scores (LBC and HBC, respectively; n = 9/group). 
Animals in the HBC group evidenced subclinical ketosis whereas LBC animals were 
metabolically healthy. For in vitro examination with β-hydroxybutyrate (BHB) as further 
stimulus, peripheral blood mononuclear cells (PBMC) counts of cows with and without 
subclinical ketosis (n = 5/group) were observed. Counts of leucocytes, granulocytes and 
lymphocytes (LY) peaked at day 1 post-partum in HBC cows, with a more marked increase in 
heifers. In subclinical ketosis LY count increased again, with significantly higher values in the 
HBC group. The red blood cell (RBC) profile was affected by parity (counts were higher in 
heifers). Hp showed a positive linear correlation with BHB and non-esterified fatty acids (NEFA; 
R
2
 = 0.41). PBMC from cows that were not pre-stressed with subclinical ketosis were more 
sensitive to increasing levels of BHB in vitro, as evidenced by both their higher proliferative 
capability and increased release of nitric oxide (NO). In summary, cows with subclinical ketosis 
showed a heightened immune response compared with metabolically healthy individuals, based 
on increased LY counts, increasing stimulative properties of PBMC and a relationship between 
Hp and typically increased values of BHB and NEFA. Concentrations of BHB in vivo during 
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subclinical ketosis did not alter the proliferative capability of bovine PBMC in vitro, which was 
first significantly decreased at a dosage of 5 mM BHB. 
Keywords: dairy cows; subclinical ketosis; haematology; heifers; ketosis; peripheral blood 
mononuclear cells; β-hydroxybutyrate 
 
Introduction 
Dairy cows undergo distinct metabolic stress during the transition from pregnancy to lactation 
and are particularly susceptible not only for metabolic diseases but also for infections. The 
proportion of dairy cows undergoing a transient period of subclinical ketosis in the first month 
after calving has recently been estimated at 50% (Esposito et al. 2014).  
This condition is characterized by increased lipomobilisation and thus rising concentrations of 
non-esterified fatty acids (NEFA) in the circulation. During the typical negative energy balance 
in the first weeks of lactation, the complete oxidation of NEFA is compromised resulting in 
increasing generation of ketone bodies (e.g. of ß-hydroxybutyrate [BHB], used as marker for 
ketosis) and also in lipid accumulation in the liver. Haptoglobin (Hp), one of the most important 
acute-phase proteins in cattle, is positively correlated to NEFA and increased liver lipid contents 
(Uchida et al. 1993). Around calving, the circulating concentrations of Hp exceed the pre-partal 
levels by a factor of about 4.5 (Hachenberg et al. 2007) and reach values up to 5 mg/ml in the 
first week after calving (Saremi et al. 2012). Similar to Hp, nitric oxide (NO) is also part of the 
inflammatory reaction in the dairy cow (Trevisi et al. 2013). These are generated by phagocytes 
(monocytes, macrophages and neutrophils), and released after enzymatic activation via cytokines. 
In human studies, increasing NEFA concentrations augment the production of reactive nitrogen 
species which are derived from NO (Valko et al. 2007). In bovine peripheral blood mononuclear 
cells (PBMC), NO production is increased after parturition (Lessard et al. 2004) and during 
mastitis (Bouchard et al. 1999).  
Investigations on the lymphocyte function in ketosis have mainly focused on the direct effects of 
BHB and NEFA. Lacetera et al. (2004) indicated that NEFA reduced mitogen-induced DNA 
synthesis and the secretion of interferon-gamma (IFN-γ) and immunoglobulin M (IgM) from 
lymphocytes of dairy heifers in vitro. Albeit at lower doses, NEFA were also shown to inhibit 
proliferation and IFN-γ mRNA expression of PBMC (Renner et al. 2013). Concentrations of 
BHB ≤1.5 mM in vivo stimulated the ability of PBMC in response to a mitogen (Dänicke et al. 
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2012), while older studies found a depressing effect on bovine PBMC proliferation (Targowski 
and Klucinski 1983) and the phagocytic activity of polymorphonuclear neutrophil leucocytes 
(Klucinski et al. 1988). Moreover, even much higher concentrations (up to 6.25 mM) did not 
suppress stimulated PBMC proliferation in vitro (Franklin et al. 1991). 
These findings relate well to the common observation that cows which seem to be most stressed 
by nutritional and environmental factors, as judged by excessive loss of body condition, are the 
most likely to become ill. Therefore, the purpose of the present study was to investigate the 
effects of elevated parameters of bovine ketosis on the immune system. Using a recently 
established model in which subclinical ketosis is induced, the responses of differential blood 
counts and various haematological variables, including the inflammatory marker Hp, were tested. 
The functionality of PBMC was assessed during the time around calving, comparing proliferative 
capability between cows with and without subclinical ketosis. In addition, PBMC were 
stimulated in vitro with increasing concentrations of BHB, the metabolite most likely to elicit the 
effects of ketosis in immune cells. 
 
Materials and methods 
Animals, trials and treatment 
The experiments were carried out at the experimental station of the Institute of Animal Nutrition, 
Friedrich-Loeffler-Institute (FLI) in Braunschweig (Germany). The animals were housed in free-
stall barns and milked twice daily. Two trials were performed for the present study. Experiments 
and procedures were conducted according to the Animal Welfare Act with the approval of the 
Lower Saxony State Office for Consumer Protection and Food Safety in Oldenburg (Germany). 
 
Trial 1 
The factorial design is described in detail elsewhere (Schulz et al. 2014). In brief, 18 pregnant 
and healthy German Holstein cows (10 pluriparous and 8 primiparous) were assigned to 2 
feeding groups (n = 9/group) according to their body condition score (BCS; 5-point scale; 
Edmonson et al. 1989). Cows with higher BCS (HBC; BCS 3.19 ± 0.09) were fed a ration 
including 60% concentrate (7.7 MJ NEL/kg dry matter [DM]), which led to energy oversupply. 
Cows with lower BCS (LBC; BCS 2.61 ± 0.09) were fed an energy-adequate ration with 20% 
concentrate (6.8 MJ NEL/kg DM). The feed was aimed to be offered for ad libitum intake. After 
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calving, the concentrate proportion was increased stepwise, regulated by a computerised feeding 
station, from 30 to 50% within the first 2 or 3 weeks for the LBC and HBC groups, respectively. 
Initial increase occurred more slowly in the HBC group, with the additional aim of stimulating 
post-partum lipolysis. The animals in the HBC group evidenced subclinical ketosis, LBC animals 
being metabolically healthy. Concentrations of BHB between 1.2 and 2.5 mM in blood serum 
were characterised as subclinical metabolic status; lower values indicated a healthy animal 
whereas higher values, combined with clinical signs, indicated clinical ketosis.  
At days 0 (control sample; 48 ± 7.19 days pre-partum) and -14, -7, -3, 1, 3, 7, 10, 14, 17, 21, 24, 
28, 35, 42 and 56 (relative to calving), blood samples were taken from the jugular vein. 
Haematology was performed in EDTA whole blood using an automatic analyzer (Celltac α 
MEK-6450, Nihon Kohden, Qinlab Diagnostik, Weichs, Germany). Fifteen variables were 
measured, including leucocytes (WBC), erythrocytes (RBC) and thrombocytes. Clinical 
chemistry data for serum were reported previously (Schulz et al. 2014). The determination of Hp 
was done using ELISA as described by Hiss et al. (2004). The limit of detection was 0.07 mg/ml. 
Functional tests of PBMC were performed on days -14, +7, +21 and +56. Unless otherwise 
stated, all chemicals were purchased from Biochrom AG (Berlin, Germany). Cells were separated 
from heparinised blood by gradient centrifugation using a Ficoll separation solution (L 6115), 
and diluted with PBS (L 1835) at a ratio of 1:1. After centrifugation (550 g, 30 min, 20°C) the 
interphase was harvested and washed with PBS (330 g, 8 min, 20°C). The pellet was resuspended 
in Roswell Park Memorial Institute (RPMI) 1640 medium (F 1295), supplemented with 5% FBS 
(S 0615), 1 M HEPES buffer (L 1613), 2 mM L-glutamin (K 0282), 5 mM β-mercaptoethanol 
(Sigma-Aldrich, Steinheim, Germany, M 7522), penicillin (100 U/ml) and streptomycin (A 2212, 
0.1 mg/ml). Samples were frozen and stored at -80°C until cell proliferation assays were 
performed. Concanavalin A (ConA, 2.5 µg/ml final, Sigma-Aldrich, Steinheim, Germany, C 
5275) was used as mitogen to stimulate T lymphocytes. Cultures were assayed in quintuplicate 
and seeded onto 96-well plates (1 ∙ 105 cells/well) with a final volume of 200 µl/well. Plates were 
incubated for 69.5 h (37°C, 5% CO2). After centrifugation (200 g, 5 min, 20°C), 100 µl of the 
supernatant were removed and Alamar Blue (AB) was added (1:10 final). The fluorescence of the 
AB reduction product resorufin was measured after 2.5 h at 540 and 590 nm (Tecan infinite 
M200, Groedig, Austria). 
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Trial 2 
Trial 2, an in vitro dose-response study with BHB, was integrated into another experiment. This 
experiment followed the same factorial design and feeding management as described for Trial 1. 
On day 7 post-partum, PBMC were obtained from the blood of 10 different pluriparous cows (5 
each LBC and HBC). The BCS was significantly different between the groups six weeks before 
expected calving (HBC, 4.05 ± 0.17; LBC, 2.80 ± 0.17). The HBC cows had serum BHB values 
indicative of subclinical ketosis (BHB ≥ 1.2 mM). LBC cows apparently stayed healthy (BHB < 
1.2 mM). 
For in vitro investigations PBMC were prepared following the same procedure as for ex vivo. β-
hydroxybutyrate (Sigma-Aldrich, Steinheim, Germany, 1668985G) was diluted in RPMI-1640 
medium to obtain a stock solution (80 mM), so that dose response studies were performed with 
20, 10, 5, 2.5, 1.25 and 0.625 mM as well as a medium control (0 mM). The metabolic activity of 
the cells was determined by AB again, also with and without ConA as mitogen stimulus.  
To assess the release of NO by macrophages in the cell culture supernatant of bovine PBMC, its 
production was determined as the accumulated level of nitrite. A dose-response examination with 
20, 10, 5, 2.5, 1.25, 0.625 and 0 mM was assayed in quintuplicates, seeded onto 96-well plates (1 
∙ 105 cells/well). Lipopolysaccharide (LPS, purified from Escherichia coli 0111:B4, Sigma-
Aldrich, L 2630 129K4025, Steinheim, Germany) was used as positive control at a dilution of 1 
µg/ml. Plates were incubated for 24 h (37°C, 5 % CO2) and then centrifuged (200 g, 5 min, 
20°C). For NO determination, a colorimetric reaction with Griess reagent [0.1 % N-(1-naphthyl) 
ethylenediamine dihydrochloride, 1 % sulfanilamide and 5 % H3PO4] was used. The cell culture 
supernatant (100 µl) and 100 µl of Griess reagent were mixed and incubated in the dark for 5 min 
at room temperature. All measurements were done in duplicate. Absorbance was measured at 540 
nm using a microplate reader (Tecan infinite M200, 5082 Groedig, Austria). Nitrite concentration 
in the samples was determined from a sodium nitrite standard curve (0.25 – 50 µM). In regard to 
concentrations below the limit of detection, a constant NO release value of 0.125 µM was 
assumed. 
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Calculation and statistics 
The results of the ex vivo and in vitro examination of PBMC were expressed as stimulation index 
(SI), which is defined as the ratio between fluorescence in the AB assay of ConA-stimulated and 
-non-stimulated PBMC: 
(1)    
The dose-response curves were fitted to the following nonlinear regression equation (Mercer et 
al. 1987):  
(2)     
where R0 is the intercept on ordinate (SI at 0 µM), Rmax is the asymptotic SI when Con converges 
to infinity, Con is the BHB concentration [mM], K05 is the SI at 0.5 ∙ (Rmax + R0) and b is the 
apparent kinetic order. In regard to the mean SI of the separate curves for HBC and LBC animals, 
R0 and Rmax were defined, respectively. 
To investigate changes in haematological variables and Hp over the peri-partal period, the 
experiment was classified into three periods: (1) days 42, 14, 7 and 3 pre-partum; (2) days 1, 3, 7, 
10 and 14 post-partum; and (3) days 17, 21, 24, 28, 35, 42 and 56 post-partum. Data for the 
measured variables were analysed as repeated measures by the Mixed procedure of SAS (SAS 
Institute 2004) and are presented as least square means (LSmeans) and standard error (SE) of the 
mean. Effects are considered significant at p-values ≤0.05 using Tukey´s test; a trend was noted 
when 0.05 < p < 0.10. These parameters were analysed using a compound symmetry covariance 
structure. The model included feeding group (HBC or LBC), time point (day/period) and parity 
(heifer or pluriparous cow) as fixed factors, including their interactions. Because of the repeated 
measurements during the experiment, individual animal effects were considered using the 
Repeated procedure. Regression analysis was carried out using Statistica 10 for the WindowsTM 
operating system (StatSoft 2011). 
Results 
Haematology 
The results for haematological variables in the different experimental periods are shown in Table 
1. There was a significant triple interaction (Group x Time x Parity) for WBC, GR, lymphocytes 
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(LY), RBC, haemoglobin (HGB) and haematocrit (HCT). The concentrations of these variables 
during the experiment are plotted in Figure 1 and 2. 
 
 
 
Figure 1. Concentrations of leucocytes (A), granulocytes (B) and lymphocytes (C) in cows of a higher 
(HBC) and lower condition (LBC). HBC cows suffered from subclinical ketosis (β-hydroxybutyrate ≥1.2 
mM in blood) during the first two weeks post-partum, while LBC cows stayed metabolically healthy. 
Comparison between primiparous and pluriparous cows (LSmeans). The statistical analysis included the 
Group (HBC versus LBC), Parity (cow versus heifer), Day of experiment and interactions. For all 
parameters, the triple interaction Group x Day x Parity was significant (p < 0.05). Fix factors and 
interactions not included in the graph are not significant (p > 0.05). Note: HBC cows (●), HBC heifers 
(○), LBC cows (▲) and LBC heifers (Δ). 
Almost all variables changed with time. The concentrations of WBC and GR showed similar 
patterns and peaked at day +1 for the HBC group, with a significant increase in heifers (Δ day -3 
to day +1: 6.77 ∙ 103 µl-1). In the LBC group, peak values were reached on day +14. Regardless 
of parity, both variables were increased on day +1 in HBC versus LBC cows. 
The LY concentration in pluriparous animals was lower than in heifers (p = 0.015). The 
concentration decreased to nadir at day +1 in LBC heifers while HBC heifers reached peak 
values on that day (Δ = 1.75 ∙ 103 µl-1, p = 0.016). During Period 2, HBC cows showed higher 
LY concentrations (p < 0.05) than LBC cows.  
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For both groups, HGB and HCT decreased significantly from Periods 1 and 2 to 3, and showed 
significant inter-group differences for Periods 2 (HGB and HCT) and Period 3 (HGB only). 
Comparable effects were found for the absolute concentration of RBC and mean corpuscular 
haemoglobin concentration (MCHC). Therefore, MCHC was affected by time, group and 
interaction, with significantly higher values for the HBC group during Period 2. Mean 
corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH), like the variable 
thrombocytes, changed with time whereas group and interaction were insignificant. The RBC 
profile was affected by parity: RBC, MCV, MCH and platelet distribution width (PDW) were 
higher in heifers than in pluriparous cows whereas HGB and HCT were lower in heifers than in 
cows (Table 1 and Figures 1 and 2). 
 
 
 
Figure 2. Concentrations of erythrocytes (A), haemoglobin (B) and haematocrit (C) in cows of a higher 
(HBC) and lower body condition (LBC). HBC cows suffered from subclinical ketosis (β-hydroxybutyrate 
≥1.2 mM in blood) during the first two weeks post-partum, while LBC cows stayed metabolically healthy. 
Comparison between primiparous and pluriparous cows (LSmeans). The statistical analysis included the 
Group (HBC versus LBC), Parity (cow versus heifer), Day of experiment and interactions. For all 
parameters, the triple interaction Group x Day x Parity was significant (p < 0.05). Fix factors and 
interactions not included in the graph are not significant (p > 0.05). Note: HBC cows (●), HBC heifers 
(○), LBC cows (▲) and LBC heifers (Δ). 
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Haptoglobin 
Time-dependent alterations in serum Hp concentrations within the experimental periods are 
shown in Table 1. For both feeding groups, the increase from Period 1 to Period 2, as well as the 
decrease from Period 2 to Period 3, was significant. Hp concentrations were affected neither by 
group nor parity, but there was a significant Period x Parity interaction. For heifers and cows, 
both the increase from Period 1 to Period 2 and the decrease from Period 2 to Period 3 were 
significant, with greater differences for heifers. In Period 2, heifers had numerically greater Hp 
concentrations than pluriparous cows (Δ = 0.56 mg/ml), albeit the level of significance was not 
reached. Haptoglobin concentrations peaked on day 3 post-partum, with 3.08 and 2.52 mg/ml for 
HBC and LBC, respectively. In the HBC group the increase from days 1 to 3 was significant. 
Nadir concentrations were observed six weeks before expected calving, with values ≤0.07 mg/ml 
in both groups. 
A moderate correlation was noted for serum Hp with BHB and NEFA values across all periods. 
Goodness of fit (R
2
) was 0.27 for BHB (p < 0.001) and 0.40 for NEFA (p < 0.001) for all cows, 
irrespective of group. A combined multiple regression of Hp versus BHB and NEFA increased 
R
2
 to 0.41 (p < 0.001) and is shown in Figure 3. The correlation effect became stronger when 
only the data of the HBC group were taken into account. For HBC cows alone, R
2
 was 0.52 (p < 
0.001) for BHB and 0.60 for NEFA (p < 0.001), and the multiple regression of Hp versus BHB 
and NEFA increased R
2
 to 0.63 (p < 0.001). 
 
 
Figure 3. Combined linear multitude 
regression (3D scatter-plot). Relationship 
between serum concentrations of haptoglobin 
(z-axis), β-hydroxybutyrate (BHB; y-axis) 
and non-esterified fatty acid (NEFA; x-axis) 
of dairy cows (n = 18) across periods: z = -
0.5588 + 1.9155x + 0.3401y (R
2
 = 0.41; p < 
0.01). Note: Period 1 (day -49 until calving 
□), Period 2 (first two weeks post-partum ●) 
and Period 3 (week 3-8 post-partum Δ). 
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Table 1. Haematological variables (whole blood analysis), including serum haptoglobin concentration, compared between cows of a 
higher condition (HBC) with β-hydroxybutyrate concentrations in blood serum indicative for subclinical ketosis (1.3 ± 0.08 mM during 
Period 2) and cows of a lower condition (LBC), which remained metabolically healthy (LSmeans ± SE). 
 LBC group (n = 9) HBC group (n = 9) Probability
‡
 
Variable Period 1† Period 2¶ Period 3+ Period 1 Period 2 Period 3 Group Period Parity 
Group 
x 
Period 
Period 
x 
Parity 
Leucocytes  
[10
3
/µl] 7.72 ± 0.46 7.22 ± 0.41 7.11 ± 0.38 8.22 ± 0.45 8.45 ± 0.42 7.48 ± 0.38 0.163 0.038 0.209 0.257   0.095 
Lymphocytes 
[10
3
/µl] 
3.03 ± 0.15 2.66 ± 0.14 2.86 ± 0.14 3.16 ± 0.15 3.14 ± 0.14 3.09 ± 0.14 0.174 0.003 0.015 0.003   0.002 
Monocytes  
[10
3
/µl] 
0.20 ± 0.03 0.18 ± 0.02 0.18 ± 0.02 0.19 ± 0.03 0.20 ± 0.02 0.22 ± 0.02 0.378 0.816 0.360 0.579   0.058 
 Granulocytes 
[10
3
/µl] 
4.20 ± 0.40 3.98 ± 0.33 3.82 ± 0.30 4.54 ± 0.39 4.72 ± 0.35 3.86 ± 0.30 0.304 0.087 0.920 0.431   0.271 
Erythrocytes  
[10
6
/µl]   5.87 ± 0.14   5.79 ± 0.13   5.44 ± 0.13   6.30 ± 0.14   6.31 ± 0.13   5.87 ± 0.13 0.024 <0.001   0.039 0.617   0.306 
Haemoglobin  
[g/dl] 
  9.63 ± 0.21   9.51 ± 0.19   8.80 ± 0.19 10.43 ± 0.20 10.64 ± 0.19   9.65 ± 0.18 0.002 <0.001   0.019 0.273   0.237 
Hematocrit [%] 32.45 ± 0.66 32.62 ± 0.61 29.61 ± 0.58 35.25 ± 0.65 35.74 ± 0.62 32.10 ± 0.59 0.003 <0.001   0.018 0.622   0.209 
MCV
$
 [fl] 55.68 ± 1.10 56.59 ± 1.09 54.79 ± 1.09 56.07 ± 1.10 56.82 ± 1.09 54.93 ± 1.09 0.887 <0.001 <0.001 0.684   0.783 
MCH
§
 [pg] 16.53 ± 0.34 16.49 ± 0.34 16.29 ± 0.34 16.60 ± 0.34 16.92 ± 0.34 16.48 ± 0.34 0.635 <0.001 <0.001 0.084   0.760 
MCHC║ [g/dl] 29.68 ± 0.15 29.14 ± 0.12 29.71 ± 0.11 29.57 ± 0.15 29.77 ± 0.13 30.08 ± 0.11 0.018 <0.001   0.552 0.017   0.828 
RDW
♦
 [%] 15.06 ± 0.27 15.10 ± 0.26 14.42 ± 0.25 15.10 ± 0.27 15.42 ± 0.26 14.89 ± 0.25 0.439 <0.001   0.697 0.103 <0.001 
Thrombocytes  
[10
3
/µl] 447.6 ± 25.1 479.7 ± 21.8 539.4 ± 20.5 452.9 ± 24.8 471.4 ± 22.5 516.0 ± 20.6 0.740 <0.001   0.470 0.670   0.249 
PCT
#
 [%]   0.14 ± 0.01   0.15 ± 0.01   0.17 ± 0.01   0.14 ± 0.01   0.14 ± 0.01   0.15 ± 0.01 0.156 <0.001   0.727 0.193   0.428 
PDW
◊
 [%] 17.44 ± 0.23 17.18 ± 0.20 16.81 ± 0.19 17.98 ± 0.23 17.87 ± 0.21 17.52 ± 0.19 0.013   0.002   0.006 0.872   0.527 
Haptoglobin  
[mg/ml]   0.26 ± 0.21   1.42 ± 0.17   0.38 ± 0.15   0.09 ± 0.20   1.61 ± 0.18   0.34 ± 0.16 0.959 <0.001   0.927 0.575   0.009 
Note: 
†
Period 1, 6 weeks before expected parturition until calving; 
¶
Period 2, first 2 weeks post-partum; +Period 3, week 3–8 post-partum; $MCV: mean corpuscular 
volume, 
§
MCH: mean corpuscular haemoglobin, 
║
MCHC: mean corpuscular haemoglobin concentration, 
♦
RDW: red blood cell distribution width, 
#
PCT: Relative 
volume of thrombocytes, 
◊
RDW: Platelet distribution width; 
‡
Triple interaction of Group x Period x Parity was statistically significant for the parameters leucocytes, 
lymphocytes, granulocytes, erythrocytes, haemoglobin and haematocrit. In none of the investigated parameters was the interaction Group x Parity significant. 
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PBMC proliferation ex vivo 
The SI of PBMC differed significantly over time, but was insignificant between the groups on the 
days evaluated (Table 2). In both groups, SI was lowest on day 56 after calving and differed 
significantly to all other days within the HBC group. SI was affected by parity and tended to be 
higher for primiparous versus pluriparous cows (6.89 versus 5.97, p = 0.092). Seven days after 
calving, when the HBC cows became subclinically ketotic, the SI of pluriparous cows was higher 
(7.12 ± 0.75) than that of primiparous cows (6.53 ± 0.84), and that of primi- and pluriparous LBC 
individuals (heifers: 6.14 ± 1.09; pluriparous cows: 5.52 ± 0.97) even though inter- or intra-group 
differences were insignificant.  
Within the HBC group, the mean SI of days when serum BHB value ≥1.2 mM was compared to 
that when the same cows had BHB concentrations within the physiological range. At a BHB 
concentration of ≥1.2 mM (LSmean of 1.6 mM), SI increased to 7.04, while BHB values <1.2 
mM (LSmean of 0.76 mM) resulted in lower SI (5.88 SI-units; p = 0.038). 
 
Dose-response studies in vitro 
Dose-response curves (based on SI obtained in the AB assay) were fitted to Equation (2) and 
used to calculate IC50 values. IC50 values (means ± SD) for BHB on day 7 after calving were 
6.93 ± 1.29 and 6.63 ± 2.79 mM for the LBC and HBC groups, respectively (p = 0.872). SI 
decreased significantly starting at a concentration of 5 mM BHB for both groups (Figure 4). 
Furthermore, there was a highly significant group effect and an interaction of Group x BHB 
concentration (p = 0.038).   
Table 2.  Functionality of peripheral blood mononuclear cells (PBMC), expressed as 
stimulation index (SI
†
), between cows of a higher condition (HBC) with  β-hydroxybutyrate 
concentrations in blood serum indicative of subclinical ketosis (1.65 ± 0.15 mM on day +7) and 
cows of a lower condition (LBC), which stayed metabolically healthy (LSmeans ± SE).  
 Experimental day (relative to calving)  Probability
‡
 
 Day -14 Day +7 Day +21 Day +56 
 
Group Time Parity 
Group 
x Time 
Group LBC  
(n = 9) 
8.22 ± 0.73 5.83 ± 0.73 7.46 ± 0.80 5.43 ± 0.73 
 
0.248 < 0.001 0.092 0.207 
Group HBC  
(n = 9) 
6.92 ± 0.56 6.83 ± 0.56 6.78 ± 0.56 4.00 ± 0.60 
 
Note: 
†
SI is defined as the ratio between fluorescence in the Alamar Blue assay of concanavalin A-stimulated and 
-non-stimulated PBMC; 
‡
Interactions of fixed factors (Group, Day, Parity) not listed are not significant. 
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For investigation of NO release in the supernatants of LPS-stimulated and -non-stimulated 
PBMC, 30 % of results were below the limit of detection (0.125 µM); LPS-non-stimulated cells 
predominated (70 %). Statistical analysis in the form of a graph is shown in Figure 5. Within the 
LBC group, LPS-stimulated cells without BHB (medium control) and cells incubated with 5 mM 
BHB released significantly more NO compared with LPS-stimulated cells from the LBC group 
incubated with 20 mM BHB. There were no significant differences among the groups in regard to 
the concentration of BHB for different BHB concentrations. LPS significantly increased NO 
release levels in the PBMC supernatant in both groups. Across all concentrations of BHB, LPS-
induced increase in NO was greater in LBC cows (LBC: 0.503 µM versus HBC: 0.339 µM, p = 
0.027). Setting the medium control at 100 %, NO release in the presence of BHB remained lower, 
independent of LPS application. The physiological concentration of 0.625 mM BHB for 
unstimulated cells from LBC animals proved the exception, being increased by 20% compared 
with the BHB-less control. 
 
Figure 4. Proliferative capability of bovine peripheral blood mononuclear cells in vitro, expressed as 
stimulation index (LSmeans ± SE).  
Notes: Cows with a higher body condition [HBC (■); n = 5] had β-hydroxybutyrate (BHB) concentrations 
in blood indicative of subclinical ketosis (≥1.2 mM), while cows with a lower body condition [LBC (□); n 
= 5] stayed apparently healthy (< 1.2 mM BHB). The statistical analysis included Group (HBC and LBC), 
Concentration (Conc) of BHB and Interactions.  
a - d
: Different letters indicate significant differences within the same group (p < 0.05) 
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Figure 5. Release of nitric oxide of bovine peripheral blood mononuclear cells in vitro (LSmeans ± SE).  
Notes: Cows with a higher body condition [HBC; n = 5] had β-hydroxybutyrate (BHB) concentrations in 
blood indicative of subclinical ketosis (≥ 1.2 mM), while cows with a lower body condition [LBC; n = 5] 
stayed apparently healthy (<1.2 mM BHB). Lipopolysaccharide (LPS) was used as both stimulus and 
positive control. The statistical analysis included Group (HBC and LBC), Concentration (Conc) of BHB 
and LSP (stimulated or non-stimulated) and Interactions. Interactions not included in the graph are not 
significant (p > 0.05).  
LBC without LPS (□), HBC without LPS (), LBC + LPS (), HBC + LPS (■)]. * p ≤ 0.05. 
Discussion 
It is known that nutrition plays a key role in the immune response and that nutrients and 
metabolites can influence several aspects of the immune system (Ingvartsen and Moyes 2012). 
For example, high concentrations of ketone bodies inhibit lymphocyte blastogenesis, oxidative 
burst and IgM secretion (Nonnecke et al. 1992, Sato et al. 1995) while changes in energy balance 
influence, for example, the acute-phase response and cytokine production (Moyes et al. 2009). 
Subclinical ketosis occurs mostly during the first four weeks after calving and therefore peri-
partum physiological alterations and a supply of energy with essential nutrients are likewise 
important for the immune system.  
Hematological variables 
For almost all elevated parameters, parity has a significant influence. Especially in heifers, 
concomitant peri-partum metabolic and endocrine changes include modified haematological 
variables (e.g. WBC and RBC counts, haemoglobin). In part, these modifications are normal, 
reflecting the specific status of heifers compared with pluriparous cows (Kraft and Duerr 2005, 
Mallard et al. 1998). 
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When group-specific differences were evaluated, the varying BCS of LBC and HBC animals 
during the experiment must be considered (Schulz et al. 2014). It has long been known that 
enhanced body condition increases the risk of peri-partum complications (Roche et al. 2009). A 
common cause of dystocia is the disproportion between the birth canal and the size of the foetus, 
which is particularly important in primiparous cows (Nahkur et al. 2011). An energy oversupply 
during the dry period may result in higher foetal growth rates. In the present investigation HBC 
calves appeared to have a higher birth weight but the proportion of male and female calves was 
imbalanced [HBC: 25% male (51.60 ± 2.6 kg), 75% female (40.5 ± 2.4 kg) versus LBC: 67% 
male (40.9 ± 4.1 kg), 33% female (42.4 ± 4.5 kg)]. Differences with regard to ease of calving 
between the groups were not detected but in particular HBC heifers seemed to be more prone to 
dystocia, reflected by higher concentrations of LY and GR. Haematological variables remained 
almost unaffected by subclinical ketosis. The small peaks of LY and RBC HBC heifers around 
day +10, and a significantly higher MCHC starting in Period 2 for the HBC animals, are linked to 
ketotic status. In human studies, alcohol-related fatty liver results in increased MCHC 
(Wickramasinghe et al. 1994). Pathophysiological hepatic alterations in HBC cows, characterized 
by liver lipid contents of about 15% and rising concentrations of aspartate transaminase and 
glutamate dehydrogenase (Schulz et al. 2014), indicate that hepatic stress may also be related to 
increasing MCHC. 
Serum Hp concentrations 
Based on the literature, Hp was expected to differ significant between cows with and without the 
presence of fatty liver. The present results show that Hp concentrations in ketotic cows were 
twofold higher compared with those detected by Ametaj et al. (2005) in cows with fatty liver. 
The significant Parity x Period interaction reflects an influence of parity, resulting in higher Hp 
concentrations in the primiparous cows. The case of liver lipid content showed the opposite, with 
values nearly twofold those of pluriparous compared with primiparous cows (data not shown). 
Although a pro-inflammatory situation is typical for the time around calving (Hachenberg et al. 
2007, Saremi et al. 2014), the increase in Hp concentrations seen here in primiparous cows may 
indicate that peri-partum changes were more stressful for heifers than for pluriparous cows, 
independent of feeding group. Therefore, increases in Hp concentration in pluriparous HBC cows 
due to hepatic lipidosis resulted in no significant difference between feeding groups. However, 
the heightened level of hepatic lipidosis in HBC animals was indirectly related to Hp, as 63 % of 
Hp variance could be explained by BHB and NEFA concentrations. Recent studies showed 
similar results and positive correlations, either between Hp and NEFA (Saremi et al. 2012) or Hp 
and BHB (Fathi et al. 2013).  
Functionality of bovine PBMC ex vivo and in vitro  
Several studies reported reduced lymphocyte responsiveness around calving (Mallard et al. 
1998). For example, Kehrli et al. (1989) demonstrated that lymphocyte blastogenic responses of 
Holstein heifers increased two weeks pre-partum and also reported a marked impairment of 
PBMC blastogenesis during the first week post-partum. The present results confirmed this 
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immunosuppression: the proliferative capability, expressed as SI, of PBMC from cows with no 
evidence of ketosis was higher on day 14 pre-partum than on day 7 post-partum (ΔSI = - 2.39; 
Table 2); and they are in accord with observations from Renner et al. (2012). In addition, the 
present authors expected that the proliferative capacity of lymphocytes would be greater in 
heifers than in cows (Mehrzad and Zhao 2008) and demonstrated a similar trend between primi- 
and pluriparous animals (Δ = 0.92, P = 0.092). Interestingly, the SI of pluriparous HBC cows 
peaked shortly after calving and during subclinical ketosis. This might reflect a better coping 
capacity in animals that had previously experienced such a metabolic situation, with improved 
PBMC proliferative ability. Dänicke et al. (2012) described BHB values of up to 1.5 mM in 
blood serum stimulating bovine PBMC in response to ConA. A similar calculation of the existing 
data confirmed this observation and showed that time points when BHB values were above the 
physiological range, proliferative capability was enhanced. In agreement with these results, a 
marked increase in BHB concentrations up to 1.2 mM did not impair the responsiveness of 
PBMC to ConA, which was also shown in the in vitro experiments. The present results indicate 
that the concentrations of BHB occurring in vivo during subclinical ketosis, did not alter the 
proliferative capability of bovine PBMC in vitro (BHB dosage of 1.25 mM), which was first 
significantly decreased at a dosage of 5 mM BHB. Earlier studies yielded similar results, and 
even heightened concentrations of BHB significantly diminished ConA-stimulated PBMC 
proliferation in vivo (> 6.25 mM) and ex vivo (> 2.0 mM) (Franklin et al. 1991, Sato et al. 1995). 
PBMC counts in LBC cows were not pre-stressed by subclinical conditions in vivo and were 
therefore more sensitive during the in vitro investigation, because increasing the concentration of 
BHB in vitro reduced the difference in SI for cells from LBC versus HBC cows, with analogous 
results for the release of NO in the PBMC supernatant. 
To our knowledge, the release of NO in the PBMC supernatant media, obtained from healthy 
cows and cows with subclinical ketosis, has not been reported to date. Similar to Hp, NO is 
shown to increase during inflammatory diseases such as bovine mastitis and various observations 
indicate a close relationship between tumor necrosis factor-α and NO production in lactating 
cows (Hirvonen et al. 1999, Kushibiki et al. 2003). In rat macrophages, reduced NO production 
was linked to a decreased capacity for glucose utilisation in these cells (Alvarez et al. 1996). In 
ketosis, glucose levels are diminished and PBMC in cows with greater glucose utilisation (LBC 
group) might produce more NO, accompanied by a higher susceptibility of NO-producing cells, 
compared with PBMC of cows suffering from a subclinical ketosis (HBC group). Nevertheless, 
further research, also with respect to the results of in vivo investigations, will be necessary.   
Conclusion 
The present study showed that almost all parameters were influenced by parity. Therefore, 
elevated parameters in heifers were closely related to higher peri-partum stress, related to 
increased impact associated with dystocia. Cows with subclinical ketosis showed a heightened 
immune response based on increased concentrations of LY, increasing stimulative properties of 
PBMC and a relationship between Hp and typically increased values of BHB and NEFA. 
Concentrations up to 1.2 mM BHB had no negative impact according to the proliferative 
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capability of PBMC, and inhibitory effects were limited to concentrations of 5 mM and higher 
during in vitro investigation. The PBMC count of cows metabolically healthy was not pre-
stressed by elevated BHB concentrations in vivo and was more sensitive during in vitro 
investigation, with a higher proliferative capability and increased release of NO. 
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Abstract 
The inhibition of dipeptidyl peptidase-4 (DPP4) via specific inhibitors is known to result in 
improved glucose tolerance and insulin sensitivity and decreased accumulation of hepatic fat in 
type II diabetic human patients. The metabolic situation of dairy cows can easily be compared to 
the status of human diabetes and non-alcoholic fatty liver. For both, insulin sensitivity is reduced, 
while hepatic fat accumulation increases, characterized by high levels of non-esterified fatty acids 
(NEFA) and ketone bodies. Therefore, in the present study, a DPP4 inhibitor was employed (BI 
14332) for the first time in cows. In a first investigation BI 14332 treatment (intravenous 
injection at dosages of up to 3 mg/kg body weight) was well tolerated in healthy lactating 
pluriparous cows (n = 6) with a significant inhibition of DPP4 in plasma and liver. Further testing 
included primi- and pluriparous lactating cows suffering from subclinical ketosis (β-
hydroxybutyrate concentrations in serum > 1.2 mM; n = 12). The intension was to offer effects of 
DPP4 inhibition during comprehensive lipomobilisation and hepatosteatosis. The cows of 
subclinical ketosis were evenly allocated to either the treatment group (daily injections, 0.3 mg 
BI 14332/kg body weight, 7 days) or the control group. Under condition of subclinical ketosis, 
the impact of DPP4 inhibition via BI 14332 was less, as in particular β-hydroxybutyrate and the 
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hepatic lipid content remained unaffected, but NEFA and triglyceride concentrations were 
decreased after treatment. Owing to lower NEFA, the revised quantitative insulin sensitivity 
check index (surrogate marker for insulin sensitivity) increased. Therefore, a positive influence 
on energy metabolism might be quite possible. Minor impacts on immune-modulating variables 
were limited to the lymphocyte CD4
+
/CD8
+
 ratio for which a trend to decreased values in treated 
versus control animals was noted. In sum, the DPP4 inhibition in cows did not effect glycaemic 
control like it is shown in humans, but was able to impact hyperlipemia, as NEFA and TG 
decreased. 
Introduction 
Dipeptidyl peptidase-4 (DPP4) plays a major role in glucose metabolism and is responsible for 
the degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1). Human GLP-1 is 
released from the small intestine in response to oral glucose [1]. It stimulates insulin secretion via 
activating specific receptors on the islet β-cells, suppresses glucagon secretion, inhibits gastric 
emptying and reduces appetite [2]. Furthermore, chronic elevated concentrations of GLP-1 were 
shown to result in reduced hepatic fat accumulation and significantly lower TG concentrations in 
rat and mouse model [3]. However, after enzymatic degeneration via DPP4, which occurs within 
minutes following ingestion, only 10-20% of active GLP-1 remains in blood. Today, DPP4 
inhibitors are employed in human medicine to prolong the beneficial incretin effects, in particular 
to improve insulin sensitivity, with the aim to treat type II diabetes [4].  
In high-yielding dairy cows, the metabolic status around calving and the onset of lactation 
exhibits huge parallels to patients suffering from type II diabetes and non-alcoholic fatty liver 
diseases, as comprehensive physiological challenges are necessary to coordinate the metabolic 
alterations. In the transition from late pregnancy and early lactation, decreases in insulin 
concentration and peripheral insulin responsiveness suppress glucose consumption by peripheral, 
insulin-dependent tissues (skeletal muscle, adipose tissue) and thus enhance the availability of 
glucose for the insulin-independent mammary gland [5]. The adaption to the negative energy 
balance (NEB) is often related to metabolic dysfunctions, such as excessive lipid accumulation in 
the liver and ketosis [6-8], characterized by increased concentrations of non-esterified fatty acid 
(NEFA) and β-hydroxybutyrate (BHB). Due to the infiltration of fat, lesions in hepatic tissues 
appear and cause increased blood levels of specific enzymes, such as γ-glutamyl transferase (γ-
GT), aspartate transaminase (AST) or glutamate dehydrogenase (GLDH) [9]. Furthermore, a fatty 
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liver contributes the development of hepatic insulin resistance and influences body´s immune 
system negatively. In particular, the impacts of tumor necrosis factor-α and acute phase protein 
reactions are well studied in cows with fatty liver and its role in immune response [10,11].    
Little is known about the metabolism of incretins and its interaction with DPP4 in ruminants. In 
contrast to monogastric species, the cow does not rely on glucose absorption in the small intestine 
but uses short chain fatty acids from ruminal fermentation for her energy supply with propionate 
as main substrate for gluconeogenesis. However, increasing dietary energy supply has been 
shown to enhance the secretion of GLP-1 in steers [12] and abomasal infusion of lipid and casein, 
but not glucose, increased the GLP-1 concentration in cows [13,14]. The fat-induced elevation in 
circulating GLP-1 is believed to play a role in the short-term control of feed intake in cattle 
[14,15], but the wide range of tissues expressing the GLP-1 receptor (gut segments, pancreas, 
spleen and kidney) suggest that GLP-1 may have multiple physiological functions beyond the 
control of feed intake [16]. The DPP4 expression and the circulating GLP-1 concentrations in 
blood depend on stage of lactation. While GLP-1 concentrations increase with onset of lactation, 
the expression of DPP4 decreases [13,17].  
Taking the background information into consideration, DPP4 is a key enzyme in intermediary 
metabolism by regulating important glycemic pathways. Therefore, it was possible that DPP4 
inhibitors could counteract typical ketotic processes in the dairy cow. Within the present research 
a DPP4 inhibitor (BI 14332) was employed to regulate typically increased parameters of bovine 
ketosis to the physiological range, respectively to compensate a distinct NEB. Therefore, we first 
established appropriate dosage of BI 14332 to effectively decrease DPP4 activity in plasma and 
liver from healthy lactating dairy cows. The second aim was to verify the efficacy of the derived 
dose and dosing regimen in cows with subclinical ketosis based on evaluation of various 
endpoints, such as clinical-chemical parameters and immune traits as well as liver lipid 
concentration. 
Materials and Methods 
Ethic statement 
The experiments were approved by the competent authority, the lower Saxony state office for 
consumer protection and food safety (LAVES; Trial 1: file no. 33.9-42502-05-11A172, Trial 2: 
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file no. 33.14-42502-04-11/0444; Oldenburg, Germany). The regulations of the German Animal 
Welfare Act (TierSchG) in its respective edition were met.  
Experimental design 
The investigations about the pharmacokinetics and pharmacodynamics (PK/PD) of BI 14332 
were performed at the Clinic for Cattle, University of Veterinary Medicine in Hannover, 
Germany (Trial 1). The experiment aimed in evaluating the effectiveness of DPP4 inhibition in 
dairy cows with subclinical ketosis was carried out at the experimental station of the Institute of 
Animal Nutrition, Friedrich-Loeffler-Institute (FLI) in Braunschweig, Germany (Trial 2).  
Trial 1 
Six lactating and clinically healthy German Holstein cows (pluriparous) were treated with three 
different doses, i.e. 0.3, 1.0 and 3.0 mg/kg body weight (BW; injection volume: 0.01 – 0.1 
mL/kg) of BI 14332 (n = 2/dosage; i.v.). 
To evaluate the concentration of BI 14332 and the DPP4 activity in plasma, samples were 
collected 24 h before the injection, 0, 0.25, 0.5, 1, 2, 4, 6, 12, 24, and 48 h after the injection. In 
addition, liver samples were collected according to Starke et al. [18] 24 h before injection and 4, 
24 and 48 h thereafter to evaluate the hepatic DPP4 activity.  
For an in vitro activity assay, potassium EDTA plasma samples of three healthy Holstein Frisian 
cows were incubated with 0, 1, 3, 10, 30 and 100 nM BI 14332.  
Trial 2 
Using an animal model in which subclinical ketosis is induced [19]; the impact of DPP4 
inhibition via BI 14332 on metabolic variables and on immune function was investigated. β-
hydroxybutyrate concentrations between 1.2 – 2.5 mM in blood serum were defined as a 
subclinical ketotic status [20].  
The chemical compositions of concentrate and total mixed ration are shown in Table 1. For more 
details regarding feeding management refer to Schulz et al. [19]. In brief, 20 pregnant and healthy 
German Holstein cows with a mean body condition score (BCS) of 3.16 ± 0.06 [21] were 
assigned to the experimental group. For the last six weeks of parturition, cows were fed with a 
high energetic ration (7.7 MJ NEL/kg dry matter). The allocation of cows with a BCS of at least 
3.0 and a high energetic energy supply ante partum resulted in a higher condition at the time of 
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calving (called “higher condition” cows; HC). The aim was to enhance lipomobilisation post 
partum. Immediately after calving, the energy supply by concentrate feeding was reduced first 
and raised stepwise (from 30% to 50% for the first three weeks of lactation).  
Table 1. Ingredients and chemical composition of concentrate and total mixed ration. 
 Ante partum diet
a
 Post partum diet
b
 
    Concentrate TMR
 
Concentrate TMR 
Ingredients, %     
 Wheat 41.0  41.0  
 Dried sugar beet pulp 30.5  30.3  
 Rapeseed meal 20.0  20.0  
 Soybean meal 6.5  6.5  
 Vitamin/mineral premix 2.0
c
  2.0
d
  
 Calcium carbonate -  0.2  
Dry matter (DM), g/kg 877 489 875 393 
Nutrients [g/kg DM]     
 Crude ash 58 55 62 56 
 Crude protein 197 140 202 122 
 Ether extract 27 33 28 32 
 Crude fibre 101 163 72 194 
 Acid detergent fibre (ADF) 136 199 96 222 
 Neutral detergent fibre (NDF) 279 394 222 431 
Energy
e
, MJ NEL/kg DM 8.6 7.7 8.7 7.0 
a
Total mixed ration (TMR) on DM basis (40% roughage (75% corn silage, 25% grass silage) + 60% 
concentrate. 
 
b
Total mixed ration on DM basis (70% roughage (75% corn silage, 25% grass silage) + 30% concentrate. 
c
Per kg of mineral feed: 10g Ca, 60g P, 120g Na, 60g Mg, 800,000 IU vitamin A, 100,000 IU vitamin 
D3, 2500mg vitamin E, 4000mg Mn, 6000 mg Zn, 1250mg Cu, 100mg I, 35mg Co, 50mg Se
 
d
Per kg of mineral feed: 170g Ca, 50g P, 120g Na, 45g Mg, 800,000 IU vitamin A, 100,000 IU vitamin 
D3, 4000mg vitamin E, 4000mg Mn, 6000mg Zn, 1300mg Cu, 120mg I, 35mg Co, 40mg Se 
e
Calculation based on nutrient digestibilities masured with wethers (GfE, 1991) and values from feed 
tables (DLG, 1997) 
 
Two cows from HC group were excluded from the experiment because of health problems, which 
were not due to the experimental design. Out of the 18 HC cows, 12 cows developed subclinical 
ketosis (serum BHB concentration ≥ 1.2 and < 2.5 mM). Six HC cows were treated with BI 
14332 (HC-BI) over a period of 7 days (daily i.v. injections, 0.3 mg/kg BW/day) and the 
remaining six subclinical cows formed the control group (HC-Con) without treatment. 
Subclinical ketosis was diagnosed on day +3 (1 HC-Con cow), day +7 (5 HC-BI cows and 3 HC-
Con cows) or on day +10 (1 HC-BI cow and 2 HC-Con cows), relative to calving. The remaining 
six HC cows were either affected with clinical ketosis (n = 3, BHB in serum > 2.5 mM) or stayed 
apparently healthy (BHB < 1.2 mM, n = 3). Blood samples were collected at day “0”, i.e. 48 ± 
7.2 days before expected calving, and then on day -14, -7, -3, +1, +3, +7, +10, +14, +17, +21, 
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+24, +28, +35, +42 and +56 (relative to calving) from the V. jugularis; liver biopsies were taken 
on day -14, +7, +21, +35 and +56.  
Sample Preparation and Analysis 
Trial 1 
The DPP4 activity in plasma and liver was assessed by a semi-quantitative assay with 
fluorescence detection at the Institute for Clinical Research and Development (Mainz, Germany). 
The method was validated for the detection of DPP4 activity in human plasma samples [22]. The 
dose dependently inhibition of DPP4 by increasing BI 14332 in nanomolar concentrations (Fig. 
1) showed that DPP4 activity in bovine samples is detectable by the method as well. The 
fluorescence measured as relative fluorescence units (RFU) is equivalent to the DPP4 activity in 
the sample. The baseline/pre-dose activity was set to 100% and all other activities measured in 
blood samples of the individual cows were calculated as the respective percentage of the baseline 
DPP4 activity. 
 
Fig. 1. Dipeptidyl peptidase-4 (DPP4) activity assessed in vitro. Potassium EDTA plasma samples of three 
healthy dairy cows were incubated with different concentrations of BI 14332 (0, 1, 3, 10, 30 and 100 nM; 
469 g/mol). The concentration of BI 14332 was significant (P = 0.006). a, b, c: Different letters indicate 
significant differences between dosages (P < 0.05, Tukey test). 
 
Homogenized liver samples (20 mg) were mixed with 450 µL DPP4 tissue buffer (25 mM 
HEPES, 140 mM NaCl, 80 mM MgCl2 and 11.25 mM Triton x-100). The DPP4 tissue buffer 
containing liver material was collected in a vial, centrifuged (1780 g, 10 min, 4 °C) and the 
resulting supernatant was stored at -80 °C until analysis for DPP4 activity. 
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The concentration of BI 14332 in blood plasma was analyzed by the Pharmacelsus GmbH 
(Saarbrücken, Germany) via LC-MS/MS (Surveyor MS Plus HPLC system, Thermo Fisher 
Scientific), connected to a TSQ Quantum Discovery Max (Thermo Fisher Scientific) triple quad 
mass spectrometer. Data handling was done using the standard software Xcalibur 2.0.7.  
 
Trial 2 
Clinical chemistry [BHB, NEFA, triglycerides (TG), glucose, γ-glutamyl transferase (γ-GT), 
aspartate transaminase (AST), glutamate dehydrogenase (GLDH)] was assessed in serum using 
photometric methods (Eurolyser, Type VET CCA, Eurolyser Diagnostica GmbH). A 
radioimmunoassay was used to quantify the serum insulin concentrations (IM3210, Insulin 
IRMA KIT, Immunotech, Beckman Coulter). This immunoradiometric test was a “sandwich” 
type assay. The antibodies used (mouse monoclonal) were directed against two different insulin 
epitopes. The assay was performed according to the manufacturer’s instructions. The intra-assay 
CV was 7.6 %, and the inter assay CV was 10.7 %. The lowest detection limit was 3.95 µU/ml. 
Haptoglobin (Hp) was measured by ELISA as described elsewhere [23] and the total lipid content 
in liver samples (~100 mg) was assessed using a gravimetrical method [18].  
The daily dry matter intake (DMI) was recorded for the whole experimental time (computerized 
feeding station: Type RIC, Insentec). Milking took place twice a day at 05.30 and 15.30. Milk 
yield was recorded using automatic milk counters (Lemmer Fullwood GmbH). 
Hematological analyses were performed in EDTA whole blood using an automatic analyzer 
(Celltac α MEK-6450, Nihon Kohden, Qinlab Diagnostik).  
Functional tests (ex vivo) of peripheral blood mononuclear cells (PBMC) were performed in 
samples from days -14, +7, +10, +14, +21 and +56 (relative to calving) using the Alamar Blue 
assay (AB). Concanavalin A (ConA, 2.5 µg/mL final, Sigma-Aldrich) was used as mitogen to 
stimulate T-lymphocytes. Further details were described previously [24].  
For the calculation of CD4
+
/CD8
+
 T-cell population and its CD4
+
/CD8
+
 ratio from data generated 
by flow cytometry, days relative to calving where pooled in accordance to treatment [day “0” and 
day -14 (“ante-partum”), two days of treatment (“treatment”), after treatment, i.e. day +17 until 
day +28 post-partum (“2 weeks post treatment”) and day +35, +42 and +56 post-partum (“end of 
trial”)]. A detailed description of the measurements is provided by Stelter et al. [25]. Samples 
were double stained with monoclonal antibodies for CD4
+
 (mouse anti bovine CD4:FITC) and 
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CD8
+
 (mouse anti bovine CD8:RPE) or the corresponding isotype controls (mouse IgG2a 
negative control: RPE and mouse IgG2b negative control: FITC; all AbD Serotec). 
Statistics and Calculations 
Trial 1 
The pharmacokinetic parameters were performed using non-linear regression via STATISTICA 
10 [26]. The time course of plasma concentration of BI 14332, Cp, was expressed by a sum of 
two exponential functions:  
 
where ai and bi are hybrid coefficients and exponential terms, t is time, and n is the number of 
exponential terms. According to Frey and Löscher (2009) from the data obtained, area under the 
concentration-time curves from 0 to 24 h (AUC), terminal half-life (t1/2), total body clearance 
from 0 to 24 h (Cl24h), the Volume of distribution (Vd), and the average steady state concentration 
(Css) were calculated. 
Area under the curve of DPP4 activity in plasma and liver from 0 to 24 h was calculated using 
the linear trapezoidal rule: 
 
Trial 2 
Insulin sensitivity was estimated by the Revised Quantitative Insulin Sensitivity Check Index 
(RQUICKI) [27]: 
 
The results of the ex vivo examinations of PBMC were expressed as stimulation index (SI), 
defined as ratio between the fluorescence in the AB assay of ConA stimulated and nonstimulated 
PBMC: 
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For statistical analyses the SAS software package [28] was used. Evaluation of goodness of fit 
was carried out using the corrected Akaike information criterion. All parameters evaluated were 
compared as dependent variable by the MIXED procedure with a compound symmetry 
covariance structure. Treatment (HC-Con vs. HC-BI) was considered as fixed factor and 
sampling dates (time) as a repeated effect, and their respective interaction were included into the 
model. All results are presented as least square means (LSmeans) and standard errors (SE). 
Effects were declared to be significant when P-values were ≤ 0.05 after Tukey test for post-hoc 
analysis, whereas a trend was noted when 0.05 < P < 0.10. 
Data evaluation of hematology, proliferative capability (SI) and clinical chemistry based on 
pooled sampling days (“week of treatment/observation”, “1st week after treatment/observation” 
and “2nd week after treatment/observation”). The day with first occurrence of serum BHB 
concentration ≥ 1.2 mM (day of classification) was set as covariate. Data evaluation of milk yield 
and DMI based on weekly mean values. The first week of lactation was set as covariate. For the 
proliferative capability, the SI of day +7 post partum was set as covariate. The remaining 
variables (liver lipid content, parameters of glycemic control, phenotyping T-lymphocytes) were 
analyzed in accordance to the evaluated sampling days, as described above.  
Results 
Trial 1  
Investigations in vitro 
The DPP4 activity in EDTA plasma samples decreased significantly starting at a concentration of 
3 nM (≙ 1.407 ng/mL) BI 14332 as shown in Fig. 1. At 100 nM (≙ 46.9 ng/mL) the remaining 
DPP4 activity was 15.1%. 
Pharmacokinetics and pharmacodynamics 
The single administration of BI 14332 at 0.3, 1.0 or 3.0 mg/kg BW was well tolerated and a clear 
BI 14332 plasma concentration-dependent inhibition of the DPP4 activity both in plasma and 
liver was noted (Fig. 2). The PK/PD variables of BI 14332 and DPP4 activity in plasma and liver 
are represented in Table 2. The AUC regarding BI 14332 in plasma were dose-dependently 
increase. The t1/2 of BI 14332 was highest for the 0.3 mg/kg BW dosage group, with a 10.5 to 23 
h range. The Vd and Cl24h were greatest when 3 mg/kg BW was applied. The Css decreased 
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dose-dependently, starting with the highest dosage of BI 14332. Plasma DPP4 activity (Fig. 2A) 
was significantly inhibited by BI 14332 at all dosages with a remaining maximum activity of 
14%, which was in line with an inhibitory power of 86% (1 mg/kg BW; 15 min after injection). 
The single dose of 1 mg/kg also showed the lowest inhibition at 24 h after injection (~ 70%), 
while inhibition by the other two dose groups were greater and quite similar (81-87%). Forty-
eight hours after injection, the cows treated with 0.3 and 3 mg/kg still had an inhibition of DPP4 
activity of about 82% versus 74% for the 1 mg/kg dosage group (P < 0.05). In liver, the AUC of 
DPP4 activity was decreased with increasing dosage (Fig. 2B). 
 
 
Fig. 2. Inhibition of plasma (A) and liver (B) dipeptidyl peptidase-4 (DPP4) activities after injection of BI 
14332. BI 14332 was administered in a single dose of 3 [■], 1 [▲] and 0.3 [●] mg/kg body weight in dairy 
cows (n = 2/group). Plasma samples (V. jugularis) were taken 24 h before and immediately before (time 
zero “0”) injection, as well as 0.25, 0.5, 1, 2, 4, 6, 12, 24 and 48 h post injection. Liver was biopsied 24 h 
before injection, as well as 4, 24 and 48 h thereafter. 
The relationship between the BI 14332 concentration in plasma and the corresponding DPP4 
activity in plasma and liver is depicted in Fig. 3, well approximated by a power function. With 
increasing plasma concentrations of BI 14332 (x-axis), a negative slope for DPP4 activity (y-
axes) was observed in liver: y = 7.72x-0.589 (r
2
 = 0.72) and in plasma: y = 935.31x-0.081 (r
2
 = 
0.76). 
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Table 2. Pharmacokinetic parameters of BI 14332 and dipeptidyl peptidase-4 (DPP4) in plasma and liver of six healthy German 
Holstein cows treated with different dosages of BI 14332 [3, 1 and 0.3 mg/kg body weight (BW); n = 2/dosage group]
a
. 
BI 14332 
Dosage 
3 mg/kg BW
b
 1 mg/kg BW
b
 0.3 mg/kg BW
b
 
Cow 1 Cow 2 Mean Cow 3 Cow 4 Mean Cow 5 Cow 6 Mean 
Plasma          
AUC24h [ng•h/mL] 2076 2784 2430 1769 773 1271 809 783 796 
t1/2 [min] 198 289 243 116 173 144 630 1386 1008 
Vd [L/kg BW] 17.07 30.13 23.60 5.21 12.73 8.97 13.37 20.56 16.97 
Cl24h [mL/kg/min] 24.09 17.96 21.02 9.42 21.55 15.49 6.18 6.39 6.28 
Css [ng/mL] 86.49 115.99 101.24 71.94 30.70 51.32 33.69 32.63 33.16 
DPP4          
Plasma          
AUC24h [RFU/h] 20491 16560 18525 21034 20135 20584 15729 17914 16822 
 Δ15min [%] 90 91 91 86 86 86 88 90 89 
 Δ24h [%] 81 85 83 66 73 70 84 87 85 
Liver
c
          
AUC24h [µg•h/mL] 41 74 43 90 45 68 63 112 101 
 Δ4h [%] 96 94 94 89 89 89 77 79 78 
 Δ24h [%] 65 71 68 40 44 42 35 31 33 
a
Pharmacokinetic parameters of BI 14332 were evaluated via bi-exponential function (Stat Soft, 2011); AUC for DPP4 activity in plasma and 
liver was calculated using the trapezoidal rule.  
b
BI 14332 was administrated intravenously (i.v.); plasma samples were taken 24 h before injection, 0, 0.25, 0.5, 1, 2, 4, 6, 12, 24 and 48 h 
after injection; liver samples were taken 24 h before injection and 4, 24 and 48 h thereafter. 
c
DPP4 activity in liver was normalized to the total protein content of the samples. 
Abbreviations: AUC: area under the curve from 0 to 24 h; t1/2: terminal half-life; Vd: Volume of distribution; Cl24h: Clearance from 0 to 24 h; 
Css: average steady state concentration; Δ15min/Δ4h/Δ24h: Inhibitory power of BI 14332 regarding DPP4 activity, calculated as difference before 
BI 14332 application and the first sample post injection (i.e. 15 min post injection in plasma and 4 h post injection in liver) and 24 h after 
injection, respectively.  
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Fig. 3. Inhibition of dipeptidyl peptidase-4 (DPP4) activity in plasma and liver after injection of BI 14332. 
BI 14332 was administered in a single dose of 3, 1 and 0.3 mg/kg body weight (BW) in dairy cows (n = 
2/group). Plasma samples were taken 0.25, 0.5, 1, 2, 4, 6, 12, 24 and 48 h after the injection (V. jugularis; 
3 mg/kg BW [□]; 1 mg/kg BW [Δ]; 0.3 mg/kg BW [○]). Liver samples were obtained by biopsy 4, 24 and 
48 h after the injection (3 mg/kg BW [■]; 1 mg/kg BW [▲]; 0.3 mg/kg BW [●]). BI 14332 (x-axis) was 
shown to have a strong negative impact on DPP4 activity (y-axes), well approximated by a power function 
(represented as quasi linear model via log-log transformation) in liver: y = 7.72x
-0.589
 (r
2
 = 0.72) and 
plasma: y = 935.31x
-0.081
 (r
2
 = 0.76). 
Trial 2 
Clinical chemistry and hepatic lipid content 
An overview of the clinical chemical parameters is given in Table 3. A significant group*time 
interaction was shown for NEFA, TG and GLDH. All three variables changed significantly with 
time and were additionally influenced by treatment. For TG, this was indicated by a significantly 
lower concentration in the HC-BI cows during the 1
st
 week after treatment compared to the HC-
Con cows. For NEFA, there was a significant decrease in the concentration between the week of 
treatment to the 1
st
 and the 2
nd
 week post treatment, only within the HC-BI group, while GLDH 
increased significantly in the HC-Con cows and peaked in the 2
nd
 week post observation. Further 
time-dependent alterations were detected for glucose, insulin, AST and γ-GT. Glucose and 
insulin concentrations were significantly greater two weeks post observation than during 
observation in the HC-Con group. For more detailed evaluation of variables describing glycemic 
control, Fig. 4 shows RQUICKI and the variables necessary to calculate the index (NEFA, 
glucose, insulin). The figure reveals significant changes relative to calving and in accordance to 
treatment. On day +10 post partum, NEFA, glucose and insulin peaked within the HC-BI group, 
PAPER III   
 
64 
 
while RQUICKI decreased to a nadir at that day. For the HC-Con cows there was the opposite 
effect as substantiated by the significant interaction between group and day for RQUICKI. 
Starting on day +14 until day +21 post partum, RQUICKI differed markedly between the 
experimental groups, with higher values for the HC-BI cows. 
 
 
 
Fig. 4. Concentrations of non-esterified fatty acids (NEFA), glucose and insulin in serum, and insulin 
sensitivity (RQUICKI) in cows with subclinical ketosis. With the first occurrence of serum β-
hydroxybutyrate concentrations ≥ 1.2 mM, cows were treated with BI 14332 [(—) n = 6] or stayed 
untreated as control [(···) n = 6]. Within the BI 14332 treatment group subclinical ketosis was diagnosed 
on day +7 (5 cows) and on day +10 (1 cows), relative to calving. Dosage of BI 14332 was 0.3 mg/kg body 
weight, applied i.v. once a day over a period of 7 days. The statistical analysis included group (BI 14332 
treatment vs. control), experimental day (1
st
 day post partum until 56
th
 day post partum), and the 
interaction (P < 0.05, Tukey test). Experimental day differed significantly for all parameters. [NEFA (♦), 
Glucose (▲), Insulin (●), RQUICKI (■)]. 
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Table 3. Effects of dipeptidyl peptidase-4 (DPP4) inhibition via BI  14332 to blood serum variables of clinical chemistry and insulin sensitivity of 
cows with subclinical ketosis (LSmeans ±SE). 
 HC-BI (n = 6)
a
 HC-Con (n = 6)
a
 Probability
c
 
Parameter 
Day of  
classification
b
 
Treatment 
1
st
 week  
after  
treatment 
2
nd
 week  
after  
treatment 
Day of  
classification
b
 
Observation 
1
st
 week  
after  
observation 
2
nd
 week 
after 
observation 
group time 
group 
x 
time 
BHB [mM] 1.63 ± 0.65 1.77 ± 0.38 1.07 ± 0.28 1.56 ± 0.31 1.51 ± 0.23 1.44 ± 0.31 1.15 ± 0.30 1.12 ± 0.32 0.509 0.166 0.520 
NEFA 
[mM] 
0.92 ± 0.28 1.09 ± 0.10 0.53 ± 0.07 0.56 ± 0.08 0.94 ± 0.23 0.94 ± 0.08 0.75 ± 0.08 0.55 ± 0.08 0.820 < 0.001 0.026 
Triglyceride  
[mg/dL] 
11.07 ± 2.40 11.20 ± 1.10 9.03 ± 0.74 9.57 ± 0.85 12.34 ± 3.69 11.37 ± 0.87 14.70 ± 0.81 11.02 ± 0.88 0.014 0.123 0.002 
Glucose  
[mg/dL] 
50.68 ± 9.22 55.09 ± 4.49 57.64 ± 3.72 59.86 ± 3.97 63.05 ± 8.52 51.70 ± 3.93 60.84 ± 3.74 62.58 ± 3.89 0.876 0.018 0.404 
Insulin  
[mU/mL] 
5.20 ± 2.72 4.58 ± 1.79 5.78 ± 1.29 8.63 ± 1.44 6.70 ± 5.62 5.49 ± 1.46 7.17 ± 1.43 11.21 ± 1.48 0.313 0.001 0.802 
RQUICKI 0.44 ± 0.04 0.43 ± 0.02 0.47 ± 0.01 0.44 ± 0.02 0.41 ± 0.04 0.43 ± 0.02 0.42 ± 0.02 0.39 ± 0.02 0.129 0.127 0.160 
Haptoglobin  
[mg/mL] 
1.56 ± 1.63 0.31 ± 0.30 0.13 ± 0.21 0.12 ± 0.23 1.27 ± 1.22 0.76 ± 0.24 0.53 ± 0.23 0.32 ± 0.24 0.168 0.385 0.817 
AST [U/I] 108.03 ± 35.3 117.00 ± 10.8 104.86 ± 8.18 86.43 ± 8.92  96.79 ± 21.0 112.65 ± 9.07 105.11 ± 8.68 92.83 ± 9.19 0.941 0.005 0.772 
γ-GT [U/I] 18.49 ± 3.41 21.67 ± 9.01 31.50 ± 8.15 40.30 ± 8.37 19.95 ± 4.18 22.94 ± 8.44 28.54 ± 8.30 38.85 ± 8.47 0.928 0.001 0.868 
GLDH [U/I] 8.13 ± 1.56 19.89 ± 7.72 29.75 ± 6.56 27.08 ± 6.88 9.42 ± 2.59 13.59 ± 6.90 20.92 ± 6.67 39.41 ± 6.97 0.918 0.003 0.028 
aWith first occurrence of serum β-hydroxybutyrate (BHB) concentration ≥ 1.2 mM cows were treated with BI 14332 (HC-BI) or stayed untreated as control group (HC-Con). BI 
14332 was applied once a day over a period of 7 days (i.v., 0.3 mg/kg body weight). Subclinical ketosis was diagnosed on day +3 (1 cow), day +7 (8 cows) or on day +10 (3 cows) 
after calving.   
b
The day of classification (mean ± SD), which was the day with first occurrence of BHB values ≥ 1.2 mM were set as covariate, integrated in the MIXED procedure of SAS [24] 
with group and time as fixed factors (P ≤0.05; Tukey test).  
c
Significant values are shown in bold. 
Abbreviations: NEFA, non-esterified fatty acids; RQUICKI, revised quick insulin sensitivity index; AST, aspartate aminotransferase; γ-GT, γ-glutamyltransferase; GLDH, 
glutamate dehydrogenase 
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The BHB concentrations were not different between the groups and the same was true for Hp. 
The greatest Hp concentrations were detected at the day of classification in both groups; 
thereafter the concentration decreased continuously. Albeit not reaching the level of significance, 
the decrease of the Hp concentration seemed to be faster in HC-BI than in the HC-Con cows. 
There was also no significant difference for the total liver lipid content between groups (data not 
shown), even though HC-Con cows had slightly higher lipid contents than the HC-BI cows at all 
days evaluated post partum (Δ = 13.8 mg/g). For both groups the total hepatic lipid content 
differed significantly with time and highest contents were detected on day +7 after calving with 
161 mg/g (HC-BI) and 175 mg/g (HC-Con).  
DMI and milk yield  
Statistical evaluation of dry matter intake and milk yield during lactation is shown in Table 4. 
Data offered a significant time effect for the variables. Milk yield and DMI increased 
continuously for both subgroups. A group effect, respectively a significant group*time 
interaction, was not determined for the named parameters. 
Hematology and cell function 
Variables of the hematology and the SI of PBMC are shown in Table 5. White blood cells (WBC) 
were significantly influenced by time and time*group. During treatment, leucocytes and 
granulocytes counts were significantly higher in the HC-BI than in the HC-Con group. The 
decrease of the named parameters from treatment to the 1
st
 and the 2
nd
 week after treatment was 
significant in the HC-BI group. The proliferative capability of PBMC in the ex vivo assay did not 
Table 4. Effects of dipeptidyl peptidase IV (DPP4) inhibition via BI 14332 to dry matter intake (DMI) and 
milk yield of cows with subclinical ketosis (LSmean ±SE). 
 HC-BI (n = 6)a HC-Con (n = 6)a Probability 
Parameter 
Co-
variateb 
2nd week 
of 
lactation 
3rd and 
4th week 
of 
lactation  
5th until 
8th week 
of 
lactation 
Co-
variateb 
2nd week 
of 
lactation 
3rd and 
4th week 
of 
lactation  
5th until 
8th week 
of 
lactation 
group time 
group 
x 
time 
DMI [kg/d] 
13.3 ± 
2.0 
13.2 ± 
0.7 
16.5 ± 
0.6 
20.4 ± 
0.5 
12.6 ± 
2.6 
14.6 ± 
0.8 
17.4 ± 
0.6 
20.5 ± 
0.5 
0.240 0.001 0.400 
Milk yield 
[kg/d] 
30.7 ± 
5.7 
31.0 ± 
1.7 
36.5 ± 
1.6 
39.1 ± 
1.5 
30.2 ± 
4.5 
31.2 ± 
1.5 
34.5 ± 
1.4 
37.4 ± 
1.4 
0.592 0.001 0.150 
aWith first occurrence of serum β-hydroxybutyrate (BHB) concentration ≥ 1.2 mM cows were treated with BI 14332 (HC-BI) or stayed 
untreated as control group (HC-Con).  BI 14332 was applied once a day over a period of 7 days (intravenous, 0.3 mg/kg body weight). 
Subclinical ketosis was diagnosed during 1st and 2nd week of lactation (day +3, day +7 or day +10 after calving).    
bThe first week (mean ± SD) were set as covariate, integrated in the MIXED procedure of SAS [24] with group and time as fixed 
factors (P ≤0.05; Tukey test). 
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change over time. T-cell-phenotyping revealed that the CD4
+
/CD8
+
 ratio of subclinically cows 
tended to be higher for the HC-Con versus the HC-BI group (P = 0.059, Table 6). For the HC-
Con cows the increase from ante partum to treatment period was significant; due to a selective 
increase of the CD4
+
 T-cell population (~ 11%) and a slight decrease of the CD8
+
 T-cell 
population (~ 10%). In the HC-BI group, both subpopulations decreased (CD4
+
: ~ 16%, CD8
+
: ~ 
26%) during treatment. Both experimental groups showed significant time effect with highest 
ratios during observation (HC-Con: 3.28) and two weeks after treatment (HC-BI: 2.60). The 
individual CD4
+
 and CD8
+ 
cell populations differed significantly over the time, but neither group 
nor the group*time interaction were significant. 
Discussion 
Most of the findings about inhibition of DPP4 are related to type II diabetes in human patients, 
opening up new perspectives in therapy. The ketotic metabolic status of high yielding dairy cows 
during early lactation is characterized by some similarities with the metabolic situation of type II 
diabetes and fatty liver in humans [29]. 
The first aims of the current investigation were (1) to show that BI 14332 is an effective DPP4 
inhibitor and (2) to find the optimal dosage of BI 14332. Therefore, all doses resulted in an 
inhibition of DPP4 activity in plasma and liver without any indication for adverse side-effects. 
According to the PK/PD results, we considered the dosage of 0.3 mg/kg BW as most suitable. 
Albeit the dosage of 3 mg/kg BW yielded the highest AUC of BI 14332, the plasma AUC of 
DPP4 activity was quite similar in the highest and the lowest dosage group. The terminal t1/2 is 
the time required to halve the plasma concentration after reaching a steady state equilibrium and 
has to be known to provide an appropriate length for the dosing interval [30], which was sought 
to be 24 h. Results confirm dosing decision of 0.3 mg/kg BW, as t1/2 and Cl24h, i.e. the ability to 
eliminate a drug [31], offered the longest retention period in blood. 
The aim of trial 2 was to test whether inhibiting DPP4 may affect blood variables associated with 
lipid metabolism and glycemic control under catabolic condition. The results showed that the 
impact of DPP4 inhibition was less in cows of subclinical ketosis, respectively during early 
lactation. Significant changes and positive impacts were limited to the time after treatment (Table 
3; NEFA, TG, GLDH). Lower TG concentrations were also observed by Ben-Shlomo et al. [3]. 
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Table 5. Effects of dipeptidyl peptidase-4 (DPP4) inhibition via BI  14332 to hematological variables and the proliferative capability of PBMC (LSmeans ±SE). 
 HC-BI (n = 6)
1
 HC-Con (n = 6)
1
 Probability 
Parameter 
Day of 
Classification
2
 
Treatment 
1
st
 week after 
treatment 
2
nd
 week 
after 
treatment 
Day of 
Classification
2
 
Observation 
1
st
 week after 
observation 
2
nd
 week 
after 
observation 
group time 
group
x time 
SI 6.69 ± 1.29 6.05 ± 0.79 6.26 ± 0.56 3.69 ±1.42 7.27 ±1.62 6.73 ± 0.75 6.49 ± 0.64 6.80 ± 1.37 0.138 0.591 0.453 
Leucocytes  
[10
3
/µL] 
9.75 ± 2.79 10.17 ± 0.65 7.59 ± 0.47 7.14 ± 0.51 7.35 ± 3.07 7.33 ± 0.52 7.48 ± 0.50 7.05 ± 0.56 0.105 0.005 0.009 
LY [10
3
/µL] 3.30 ± 1.07 2.79 ± 0.22 2.86 ± 0.19 2.89 ± 0.20 2.93 ± 0.41 2.95 ± 0.20 2.97 ± 0.19 3.09 ± 0.20 0.549 0.642 0.927 
GR [10
3
/µL] 5.87 ± 2.01 6.74 ± 0.66 4.01 ± 0.48 3.75 ± 0.52 3.77 ± 2.95 4.00 ± 0.53 3.99 ± 0.51 3.37 ± 0.57 0.106 0.002 0.015 
EO [10
3
/µL] 0.40 ± 0.24 0.33 ± 0.12 0.39 ± 0.09 0.29 ± 0.10 0.45 ± 0.26 0.27 ± 0.10 0.34 ± 0.10 0.40 ± 0.11 0.987 0.730 0.426 
Erythrocytes  
[10
6
/µL] 
5.92 ± 0.42 5.81 ± 0.21 5.69 ± 0.19 5.53 ± 0.20 6.07 ± 0.82 5.90 ± 0.20 5.94 ± 0.19 5.87 ± 0.20 0.407 0.238 0.468 
HGB [g/dL] 10.82 ± 0.68 10.23 ± 0.42 9.90 ± 0.37 9.69 ± 0.39 10.52 ± 1.18 10.40 ± 0.39 10.38 ± 0.39 10.31 ± 0.40 0.435 0.331 0.551 
HCT [%] 36.30 ± 2.61 34.60 ± 1.36 33.48 ± 1.20  32.27 ± 1.24 35.07 ± 4.09 34.70 ± 1.26 34.59 ± 1.24 34.43 ± 1.30 0.510 0.186 0.347 
Thrombocytes 
[10
3
/µL] 
       514 ± 127     117 ± 653   1029 ± 515   1631 ± 550      453 ± 48 835 ± 561      862 ± 538     909 ± 583 0.933 0.211 0.276 
1
With first occurrence of serum β-hydroxybutyrate ≥ 1.2 mM cows were treated with BI 14332 (HC-BI) or stayed untreated as control (HC-Con). BI 14332 was applied once a 
day over a period of 7 days (intravenous, 0.3 mg/kg body weight). Subclinical ketosis was diagnosed on day +3 (1 cow), day +7 (8 cows) or on day +10 (3 cows) after calving.   
2
The day of classification (mean ± SD), which was the day with first occurrence of BHB values ≥ 1.2 mM were set as covariate, integrated in the MIXED procedure of SAS [24] 
with group and time as fixed factors (P ≤0.05; Tukey test). Significant values are shown in bold. 
Abbreviations: SI, stimulation index (ratio between the fluorescence in the Alamar Blue assay of concanavalin A-stimulated and unstimulated PBMC); LY, lymphocytes; GR, 
granulocytes; EO, eosinophile granulocytes; HGB, hemoglobin; HCT, hematocrit 
 
 
Table 6. Effects of dipeptidyl peptidase IV (DPP4) inhibition via BI 14332 to relative numbers of CD4
+
 and CD8
+
 T-lymphocytes (LSmean ±SE). 
 HC-BI (n = 6)
a
 HC-Con (n = 6)
a
 Probability 
Parameter Ante partum Treatment 
2 weeks 
after 
treatment 
End of trial Ante partum Observation 
2 weeks after 
observation 
End of trial group time group x time 
CD4
+
 [%]   28.8 ± 2.3
ab
  24.0 ± 2.9
a
 33.5 ± 2.0
b
 34.0 ± 2.37
b
  28.8 ± 2.1
a
   2.4 ± 2.7
ab
   33.2 ± 2.4
ab
  36.5 ± 2.2
b
 0.314 0.001 0.155 
CD8
+
 [%] 15.6 ± 1.2  11.6 ± 1.6  13.7 ± 1.1   14.4 ± 1.30 12.9 ± 1.2   11.5 ± 1.5 11.7 ± 1.3    13.6 ± 1.2 0.347 0.045 0.535 
CD4
+
/CD8
+
   1.85 ± 0.25 2.06 ± 0.33 2.60 ± 0.22   2.46 ± 0.27 2.29 ± 0.24
a
 3.28 ± 0.30
b
 2.90 ± 0.26
a
 2.83 ± 0.25
a
 0.059 0.001 0.245 
aWith first occurrence of serum β-hydroxybutyrate ≥ 1.2 mM cows were treated with BI 14332 (HC-BI) or stayed untreated as control group (HC-Con). BI 14332 was applied 
once a day over a period of 7 days (0.3 mg/kg body weight). Subclinical ketosis was diagnosed on day +3 (1 cow), day +7 (8 cows) or on day +10 (3 cows) after calving. 
Significant values (P ≤ 0.05) and trends (P ≤ 0.1) are shown in bold. LSmeans with different superscripts (a-b) within the same group are significantly different. 
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The researchers show significant reduced levels in DPP4-deficient rats and explain a GLP-1 
mechanism in liver which induces a signal for a low energy state. Therefore, protein kinase 
activities involved in the pathway effect a reduced expression of lipogenesis-related genes. 
Effects of DMI and milk yield showed that there was no difference between the subgroups (Table 
4), which could have explained a lower lipolysis for the HC-BI cows. Therefore, the decrease in 
NEFA was not caused by a higher DMI or a lower milk yield for those cows compared to the 
HC-Con cows.  
RQUICKI, as surrogate marker to assess insulin sensitivity, includes NEFA in the equation and 
the lower NEFA concentrations in HC-BI vs. HC-Con rather than the ones of glucose and insulin 
affected RQUICKI. However, differences between the groups were limited to diverging reaction 
over time, i.e. the interaction of time and treatment. At day +14 post partum RQUICKI was 
greater in the BI 14332 treated animals. At this stage, approximately during the middle of the 
treatment, a steady state plateau is reached and therapeutic efficacy is assumingly complete [32]. 
In a further study, RQUICKI remained unaffected during subclinical ketosis [19]. We conclude, 
that RQUICKI may be not sensitive enough to investigate alterations of insulin sensitivity in case 
of subclinical ketosis, but it is more likely that insulin sensitivity is not, or even very less, 
influenced by subclinical ketosis and a diminished sensitivity is limited to physiological changes 
around calving. Nevertheless RQUICKI was sensitive enough to show a transient improvement 
of insulin sensitivity by BI 14332. Taking into account that DPP4 inhibition was significant (Fig. 
2, Table 2) and with respect to investigations made in humans and rodents, one could assume that 
the retention period of active GLP-1 in the periphery was prolonged. If that is also true in cows, it 
may explain the positive impacts on lipaemic control. However, the support was not strong 
enough to affect the entire metabolism.  
The fact that effects of DPP4 inhibition were marginal may be linked to the short duration of the 
treatment period [2]; which was possibly reflected by GLDH. Changes in GLDH became evident 
only late [19,33] and indicated less hepatic lesions in the second week after BI 14332 treatment. 
This was not evidenced by a reduced level of hepatic fat in the HC-BI cows. A prolonged 
treatment period might affect hepatic infiltrations of lipids in a stronger way.  
Another aim of trial 2 was to investigate if the inhibition of DPP4 via BI 14332 has immune-
modulating effects. The prescribing information of sitagliptin, the first DPP4 inhibitor for clinical 
use, reports a slight increase in WBC, primarily due to a small increase of neutrophil 
granulocytes counts [34]. The HC-BI cows had already higher WBC values before the onset of 
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the treatment, with Δ = 2.40 · 103/µl at the day of classification compared to cows of control 
group. Therefore, it was questionable, if significant changes of WBC and GR counts were indeed 
related to BI 14332 or just coincided with time-related alterations around calving. Our 
investigations regarding the proliferative capability of PBMC showed similar results and 
immune-modulatory alterations were not evident. Studies employing DPP4 inhibitors showed 
that T-cell proliferation and cytokine production is inhibited by impaired DNA synthesis [35]. In 
contrast, Anz et al. [36] showed results, similar to the present. None of the tested DPP4 inhibitors 
impaired key parameters of the innate and adaptive immune response, which were included in the 
present study to assess drug safety.  
For the current investigation, immune-modulatory effects were limited to differences in 
CD4
+
/CD8
+
 ratio, which tended to be higher for the HC-Con cows (vs. HC-BI cows), with a 
significant increase after calving (~ 30%) up to 3.28. A ratio up to 2.5 suggests a physiological 
situation, while an increased ratio may indicate an immune dysregulation [37,38]. Furthermore it 
is known that DPP4 is expressed predominantly on T-lymphocytes and most of the T-cells 
expressing DPP4 belong to the CD4
+
 population (~ 56%) [39]. The inhibition of DPP4 activity 
may lower the expression of CD4
+
 and CD8
+
 T-cells. This was more pronounced for CD8
+
 cells 
and led to a better CD4
+
/CD8
+
 ratio. It suggests an impaired immune defense after calving, when 
the need for an appropriate defense is highest. In view of the concentrations of the acute-phase 
protein Hp that is commonly used as marker of inflammation, a beneficial effect of BI 14332 on 
the immune defense was not supported. Haptoglobin is assumed to be elevated by tissue lesions 
occurring during birth and by the general proinflammatory situation for the time around calving 
[40]. It positively correlates with BHB, NEFA and TG [10,24,41]. The minor impact of the DPP4 
inhibition regarding these variables may explain for the insignificant differences in Hp 
concentrations between groups. Nevertheless, in numerical terms alone, within the HC-BI group 
Hp dropped markedly by about 80% (vs. ~ 40% for HC-Con cows; Table 3) during the treatment. 
Thus a prolonged treatment period together with a concomitant improvement of hepatic lipid 
metabolism may also reduce Hp.  
Conclusions 
The DPP4 activity was determined in plasma and liver samples of dairy cows. The DPP4 
inhibitor BI 14332 reduced the enzymatic activity in vivo and showed a fast onset and a long 
lasting inhibition of DPP4. However, the DPP4 inhibition did not improve the metabolic 
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disarrangements related to subclinical ketosis. Albeit an improved lipaemic control was observed, 
as NEFA and TG were decreased after treatment. Unfortunately, the support was not strong 
enough to affect main markers of ketosis (BHB, hepatic lipid content). 
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6. General discussion and conclusion 
A recently published study underlines the relevance of subclinical ketosis in dairy herd 
management and therefore the motivation in animal science for further research. In brief, the 
authors highlighted the need to conduct more studies on the associations between subclinical 
ketosis and the risk of diseases, changes in milk production and reproductive parameters 
(Raboisson et al., 2014). The present work focused on cows suffering from a subclinical ketosis 
during early lactation with the aim to determine changes in metabolism, performance and 
parameters of the immune response (Paper I and II). The animal model will be useful for testing 
interventions available for diagnosis, prevention and treatment. The inhibition of DPP4 was a 
new possibility to influence a ketotic metabolism in cows, providing new knowledge of cows 
during subclinical ketosis and around calving (Paper III).  
The animal model of subclinical ketosis based on two relevant components – the classification of 
groups according to the BCS six weeks before expected calving and the feeding management a.p. 
and p.p.. An extended overfeeding period a.p. or feed intake restriction or deprivation during 
early lactation to induce a ketotic state p.p. were also described in other studies (Kuhla et al., 
2009; Loor et al., 2007; Petzold et al., 2015). The “Utrecht fatty liver model of dairy cows” 
(Geelen and Wensing, 2006) was aimed to find an adequate model in which hepatic lipidosis and 
associated problems of production, health and fertility can be studied. Without the classification 
of cows according to their BCS, the combination of overconditioning a.p. and feed restriction 
p.p. used herein induced an increased lipolysis in adipose tissue and TG accumulation in the liver 
following calving.  
In the present model of subclinical ketosis, the BCS six weeks before expected parturition 
included the assignment of cows with an average BCS of 3.19 to a higher condition group (HC), 
and those cows with an average BCS of 2.61 to a lower condition group (LC). In brief, body 
condition scoring has been widely accepted as the most practical method for assessing changes in 
energy reserves. An optimum early lactation BCS (3.0 to 3.5) and a controlled loss of body 
condition of 0.5 to 1.0 is associated with optimal peak milk production, health, and reproductive 
performance (Bewley and Schutz, 2008; Roche et al., 2009). Fat cows tend to lose more body 
condition during early lactation than thin cows (Lacetera et al., 2005). The same is true for 
multiparous versus primiparous cows (Domecq et al., 1997). Owing to a positive nonlinear 
relationship between calving BCS and milk yield, researchers show that maximum milk 
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production is associated with BCS at calving of 3.25 to 3.5 (Berry et al., 2007), even though cows 
with a calving BCS of ~3.5 have 2 times higher risk to develop ketosis compared to cows calving 
at BCS ≤ 3.25 (Gillund et al., 2001), respectively, compared to cows at BCS 2.0 (Rasmussen et 
al., 1999). The literature reveals the fragile balance between the request for maximum milk yield 
and the risk of ketosis, respectively, suggesting why dairy cows, especially cows of the Holstein 
breed, with higher milk production suffer from subclinical ketosis more often. In sum, the 
intensification of milk production has led to a worsening of the average body condition of the 
cow, partly as a consequence of antagonistic genetic correlations between milk yield and BCS 
(Kadarmideen and Wegmann, 2003; Pryce et al., 2011). Therefore, in the present investigation 
the selection for BCS was equivalent to a genetic selection, accompanied by the fact that indirect 
relationships to other traits are possible. For example, the BCS at calving affects systemic and 
hepatic transcriptome indicators of inflammation and nutrient metabolism in grazing dairy cows, 
whereby cows of a higher calving BCS show an up-regulated hepatic expression of peroxisome 
proliferator-activated receptor-α-targets (PPARα; one of the key hepatic transcription factors) in 
the fatty acid oxidation and ketogenesis pathways, along with gluconeogenetic genes (Akbar et 
al., 2015).  
In ruminants, most of the available glucose is derived from hepatic gluconeogenesis and 
regulation of glucose homeostasis is known to be mediated by insulin and glucagon. During 
hyperglycemia (blood glucose >79 mg/dl; (Vogel et al., 2011), insulin secretion is increased to 
maintain plasma glucose concentrations at a physiological level. The present investigation 
achieved a well-controlled blood glucose concentration and no differences between the 
experimental groups were shown (Paper I and Paper III). In contrast, the insulin concentration 
was strongly affected. The higher concentrations of insulin a.p. as a response to energy 
overfeeding (Paper I) might be a result of a higher consumption of corn, followed by increased 
gluconeogenesis and coupled with stimulated pancreatic insulin secretion. Also the combination 
with an exacerbated peripheral insulin resistance (defined as either decreased sensitivity or 
responsiveness of insulin-sensitive tissues to insulin; (Kahn, 1978) might be possible (Ji et al., 
2012). In the late pregnancy and early lactation, insulin concentration decreases and the 
peripheral insulin responsiveness suppresses glucose consumption by peripheral, insulin-
dependent tissues (skeletal muscle, adipose tissue). Thus the availability of glucose for the 
insulin-independent mammary gland is enhanced (Bell, 1995). Nevertheless, severe 
undernutrition can cause insulin levels to fall and in overweight cows hyperinsulinaemia may be 
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related to insulin resistance (Wathes et al., 2007). Owing to these observations, differences in 
insulin sensitivity between the experimental groups seemed to be expectable.  
At this point, BI 14332 may play a key role as it should improve insulin sensitivity by inhibiting 
DPP4. To our knowledge, the employment of a DPP4 inhibitor in dairy cows was tested herein 
for the first time. The increasing concentrations of GLP-1 and GIP after calving (Faulkner and 
Martin, 1999; Relling and Reynolds, 2007) are associated with an increase in gut tissue mass 
with positive impacts on nutrient absorption. A prolonged effectiveness of active GLP-1(7-36) 
p.p. via DPP4 inhibition was expected to reduce hepatic lipidosis, with positive impacts on 
energy metabolism (Paper III). This assumption was made because chronically elevated 
concentrations of GLP-1 resulted in reduced hepatic lipid contents and significantly lower TG 
concentrations in rat and mouse models (Ben-Shlomo et al., 2011). The researchers delineate a 
GLP-1 signaling pathway in the liver, in which GLP-1 induces a signal for a low energy status 
via the cAMP/AMP-activated protein kinase (AMPK) pathway, resulting in a reduced expression 
of lipogenesis-related genes. The AMPK has emerged as a key regulator of skeletal muscle fat 
metabolism. For example, it regulates the fatty acid transport into the mitochondria, the capacity 
of the fatty acid oxidation by phosphorylation (Thomson and Winder, 2009) and AMPK mediates 
the metabolic effects of hormones such as leptin, glucocorticoids or insulin (Lim et al., 2010). 
Seo et al. (2008) showed that the food intake lowering effect of GLP-1 is caused by reversing the 
fasting-induced increase in hypothalamic AMPK activity and authors conclude that anorectic 
effects of GLP-1 are mediated, at least in part, by the hypothalamus. In cattle, protein expression 
of AMPK has been investigated in the liver during mobilization of body reserves (Kuhla et al., 
2009) and was increased in adipose tissue both during early lactation (Locher et al., 2012) and 
independent from lactation with decreasing DMI (Locher et al., 2015). Furthermore, the bovine 
hepatic mRNA expression of PPARγ, a lipogenic and adipogenic gene which is down-regulated 
by activated AMPK, is negatively associated with NEFA, BHB and back fat thickness and 
positively with the Revised Quantitative Insulin Sensitivity Check Index (RQUICKI) (Saremi et 
al., 2014). Unfortunately, associations regarding pathways of AMPK and GLP-1 or other 
incretins in cows are presently lacking. In a simplified scheme and according to the own results, 
AMPK activity may have been increased during early lactation and under a status of fasting-
induced energy deficit, which was reflected by an increased lipolysis to compensate. Because BI 
14332 caused a significant inhibition of DPP4 (Paper III) it can be assumed, that a high level of 
active GLP-1(7-36) circulates in the periphery of treated cows. In this case AMPK activity might 
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remain on a mean level and the NEB-induced lipolysis will be less strong. As a possible point of 
entry, the lower TG and NEFA concentration in bovine serum and the higher RQUICKI index 
after BI 14332 treatment are conceivably (Paper III). With respect to the DMI and unlike to 
human studies, a reduced appetite was not observed with BI 14332 treatment (Paper III). For the 
present investigation, this fact has to be considered positively, since physiologically decreased 
DMI around calving was not further strengthened. Selected variables of the clinical chemistry are 
summarized in Table 1. The table reflects the first and the second week after calving when the 
risk of ketosis is highest (McArt et al., 2011) and 80% of the HC cows showed a ketotic status. 
The variables assessed were only marginally influenced by the BI 14332 treatment. The data set 
demonstrates that HC cows treated with BI 14332 do not reach the same metabolic status as cows 
of the NC group, with the exception of TG. Triglyceride concentrations for HC-BI cows were as 
high as for the NC cows on day +14 p.p. and therefore 20% lower than for the HC-Con cows. A 
similar development was observed for the NEFA concentration, with values lower for HC-BI 
cows than for HC-Con cows, but higher than those for NC cows. Particularly interesting for the 
present investigation, RQUICKI showed a significant interaction between group and time within 
the two evaluated days and beyond the three experimental groups, as well as the highest index 
value on day +14 for the HC-BI cows, when BI 14332 treatment was almost terminated. By now, 
RQUICKI is an established surrogate marker for insulin sensitivity, because in lactating cows 
about 80% of the cellular glucose uptake occurs independently of insulin (mainly by the 
mammary gland), whereby the suitability of glucose tolerance tests is inhibited (Holtenius and 
Holtenius, 2007). Paper I showed that there was no difference in RQUICKI between cows with 
subclinical ketosis and cows that are metabolically healthy and it is questionable if this surrogate 
marker is useful for assessing insulin sensitivity in cows suffering from a metabolic disorder. In 
healthy cows RQUICKI is positively associated to insulin and glucose clearance, and negatively 
to BCS (Balogh et al., 2008). However, in periparturient cows with changes in BHB, RQUICKI 
remained unaffected by any measured variable during glucose or insulin tolerance test, and did 
not correlate with BCS or BCS loss (Kerestes et al., 2009). In the same study, cows with long-
term hyperketonemia had decreased peripheral insulin sensitivity and glucose responsiveness to 
insulin, while RQUICKI was increased, and authors indicated RQUICKI as an index with low 
discrimination power in diagnosing insulin sensitivity in cows affected by metabolic diseases 
(Kerestes et al., 2009). 
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Table 1. Variables of clinical chemistry to elicit information about metabolic health of three different experimental groups
†
 of primi- and 
pluriparous cows. 
  
BHB [mM] NEFA [mM] 
Triglyceride  
[mg/dL] 
Glucose  
[mg/dL] 
Insulin  
[mU/mL] 
RQUICKI 
Haptoglobin  
[mg/mL] 
AST [U/I] γ-GT [U/I] 
LC 
Day +7 
0.76 ± 0.27 0.58 ± 0.08 10.65 ± 1.06 62.55 ± 3.28   9.01 ± 1.84 0.43 ± 0.01 1.59 ± 0.46 77.97 ± 10.38 16.99 ± 2.03 
HC-Con 1.31 ± 0.31 1.03 ± 0.10 13.44 ± 1.26 65.15 ± 3.88   5.78 ± 2.00 0.39 ± 0.02 2.70 ± 0.54 94.94 ± 12.29 17.00 ± 2.40 
HC-BI 1.43 ± 0.41 1.28 ± 0.13 15.19 ± 1.65 54.84 ± 5.08   4.95 ± 2.62 0.41 ± 0.02 0.96 ± 0.71 94.57 ± 16.09 17.62 ± 3.15 
LC 
Day +14 
0.65 ± 0.27 0.42 ± 0.08   9.93 ± 1.06 63.71 ± 3.28 12.58 ± 1.69 0.42 ± 0.01 1.10 ± 0.46 65.15 ± 10.38 17.04 ± 2.03 
HC-Con 1.07 ± 0.42 0.86 ± 0.13 12.86 ± 1.66 58.10 ± 5.19   6.22 ± 2.69 0.41 ± 0.02 0.42 ± 0.71 92.09 ± 16.11 20.18 ± 3.01 
HC-BI 1.53 ± 0.42 0.63 ± 0.13   9.41 ± 1.68 56.45 ± 5.20   3.81 ± 2.68 0.48 ± 0.02 0.17 ± 0.72 96.84 ± 16.42 20.74 ± 3.20  
Probability 
Group 0.136 < 0.001 0.046 0.309 0.031 0.157 0.420 0.205 0.760 
Parity 0.124 0.438 0.036 0.011 0.045 0.010 0.576 0.014 0.333 
Time 0.762 0.005 0.102 0.667 0.593 0.046 0.012 0.640 0.201 
Group*Time 0.891 0.130 0.288 0.502 0.497 0.039 0.186 0.763 0.580 
†
Cows of higher condition group (HC) suffered from subclinical ketosis, defined as BHB concentration in blood serum ≥1.2 mM. Cows of lower condition group (LC, n = 
9) stayed apparently healthy. Subclinical ketosis was diagnosed on day +3, +7 or +10 post partum. With first occurrence of subclinically BHB concentrations, cows of HC-
BI (n = 6) group were treated with BI 14332 (dipeptidyl peptidase 4-inhibitor; intravenous; 0.3 mg/kg body weight, 7-days period), while HC-Con (n = 6) cows remained 
untreated as control group.   
Significant values (p < 0.05) are shown in bold. 
Abbreviations: BHB. β-hydroxybutyrate; NEFA. Non-esterified fatty acids; RQUICKI. Revised quick insulin sensitivity index; AST. aspartate aminotransferase; γ-GT. γ-
glutamyltransferase 
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The higher index in cows treated with BI 14332 was attributable to the decreased NEFA 
concentration (Paper III, Table 1), and RQUICKI seems to be useful to investigate differences 
reflected e.g. by breed (Bossaert et al., 2009), by parity (Singh et al., 2014) or by various stages 
of lactation (Bjerre-Harpoth et al., 2012). However, RQUICKI may not be sensitive enough to 
investigate sensitive metabolic alterations, such as short-term changes or metabolic diseases, 
especially in case of subclinically disorders (Kerestes et al., 2009). RQUICKI may also not be a 
reliable marker across the whole range of BCS (Jaakson et al. 2013). Furthermore, the digestive 
physiology of ruminants complicates investigations of fasting blood concentrations to prepare 
steady state protocols and calculate surrogate insulin sensitivity indices as suggested in humans. 
Regarding variables which are closely associated with the immune system, a slight influence of 
subclinical ketosis was observed (Paper II). Interestingly, PBMC of cows which were not pre-
stressed by subclinical ketosis in vivo were more sensitive to increasing levels of BHB in vitro as 
evidenced by both their proliferative capability and the increased release of nitric oxide in the 
PBMC supernatant. As slightly diminished immune cell responsiveness might imply an increased 
risk for different diseases (e.g. endometritis, mastitis), consequences on the immune system in 
case of subclinical ketosis are expectable, with negative impacts on health in general, on fertility 
and performance. First significant effects on the proliferative capability of PBMC were detected 
at a dosage of 5 mM BHB. Such BHB concentrations can be expected during clinical ketosis and 
starvation. Therefore, it is evidenced that next to NEFA (Lacetera et al., 2004; Scalia et al., 2006; 
Ster et al., 2012) even BHB, as most important ketone body, elicits effects of immune cells. 
However, the inhibition of DPP4 via BI 14332 seemed not to alter the proliferative capability of 
bovine PBMC (Paper III). Anz and colleges showed similar results in humans and mice and 
conclude that these findings are confirming the drug safety (Anz et al., 2014). In view of 
immune-modulated changes, the lymphocyte CD4
+
/CD8
+
 ratio tended to be lower in BI 14332 
treated cows at the time of treatment. An appropriate CD4
+
/CD8
+
 ratio is important to sustain T-
cell homeostasis and immune responses. It has been proven that most of the T-cells expressing 
DPP4 belong to the CD4
+
 population, whereby expression is tightly regulated upon T-cell 
activation with an increased DPP4 expression for several days (Lee et al., 2013). If this 
assumption also applies for cattle, the results show that an immune suppression for BI 14332 
untreated cows and the subsequent increased susceptibility to diseases may be associated to an 
imbalance in the T-cell subpopulation, followed by a reduced T-cytotoxic immune response. The 
correlation observed in Figure 3 between NEFA and the CD4
+
/CD8
+
 ratio point to the relation 
GENERAL DISCUSSION AND CONCLUSION   
 
82 
 
between increased hepatic lipidosis and induction of an immune dysregulation. It is known, that 
an increased hepatic fatty infiltration correlates strong positively with inflammatory markers, 
such as haptoglobin (Saremi et al., 2012, Paper II), serum amyloid A (Fathi et al., 2013), or 
various cytokines (Trevisi et al., 2012). As both, NEFA and CD4
+
/CD8
+
 ratio, were influenced 
by DPP4 inhibition, a relationship seems possible. As shown in Figure 3, the CD4
+
/CD8
+
 ratio 
(y-axis) increased with increasing NEFA (x-axis) concentrations linearly with a positive slope: y 
= 1.376x + 1.9336, which suggests a moderate relationship (r = 0.40). The largest scattering with 
highest CD4
+
/CD8
+
 ratios and NEFA values were shown for the HC-Con cows (blue triangles), 
but also for the other two groups outliers were present. According to physiological ranges, 
defined as maximum CD4
+
/CD8
+
 ratio of 2.5 (Mehrzad and Zhao, 2008) and 0.63 mM NEFA in 
blood (Dirksen et al., 2012), 48.3% of all dots were within this range.  
 
Figure 3. Linear regression between the serum concentrations of NEFA (x-axis) and the 
lymphocytic CD4
+
/CD8
+
 ratio (y-axis) for the time around calving and during subclinical ketosis. 
Lower conditioned cows stayed metabolically healthy during the experimental time (LC ●; n = 9). Higher 
conditioned cows suffered from subclinical ketosis post partum, defined as β-hydroxybutyrate 
concentrations in blood ≥ 1.2 mM, and were either treated with BI 14332 to inhibit dipeptidyl peptidase-4 
(HC-BI ♦; n = 6) or stayed untreated as control (HC-Con ▲; n = 6). The CD4+/CD8+ ratio increased with 
increasing NEFA concentrations linearly with a positive slope and a moderate correlation (r = 0.40) was 
observed: y = 1.376x + 1.9336 [Correlation was calculated using Pearson correlation coefficient at P ≤ 
0.05].  
Taking older studies and their findings about the lack of association between GIP or GLP-1 and 
insulin into account, it is doubtful how useful attempt to treat ketotic situation by inhibition of 
DPP4 are. For the present investigation the GLP-1 concentration in blood could not be measured. 
Owing to matrix effects the results of the used multispecies assay (Enzyme Linked 
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Immunosorbent Assay; species reactivity: mammals) were not evaluable. Therefore, the 
pathways are still unclear and precise statements regarding the interaction of DPP4, GLP-1 and 
the generated data are lacking, but there is no doubt that further investigations have also to reflect 
the incretin concentrations to clarify that the incretin activity is prolonged during DPP4 
inhibition. Even a more sensitive evaluation of insulin sensitivity (e.g. via hyperinsulinemic 
euglycemic clamp) may be useful, also to confirm findings made by RQUICKI. An explanation 
for the minor impact of DPP4 inhibition on variables of energy balance, ketogenesis and/or the 
immune system may be the duration of treatment period. The BI 14332 was kept rather short 
compared to studies of humans and rodents (Drucker and Nauck, 2006), where test subjects are 
usually treated over a period of several weeks. In addition, in humans further proteases such as 
neutral endopeptidase may inactivate up to half of the GLP-1 entering the circulation (Plamboeck 
et al., 2005). Human neutral endopeptidase is also known as neprilysin or CD10 and has already 
been demonstrated in the mammary glands of dairy heifers (Safayi et al., 2012). Therefore, it 
seems possible, that beside DPP4 other peptidases (i.e. DPP8, DPP9, fibroblast activation 
protein; Chen and Jiaang, 2011; Lankas et al., 2005) are able to inactivate GLP-1 and/or other 
incretins in cattle, with potential impacts on energy metabolism.   
Conclusion 
Under the present conditions (e.g. dosage, duration) a significant inhibition of DPP4 via BI 
14332 was shown. Temporarily, the inhibition influenced clinical chemical variables, with 
positive impacts on energy metabolism. A long-term modeling via BI 14332 was not overserved. 
In particular, BHB, as indicator for subclinical ketosis, remained unaffected. Also the impact on 
immune-modulating variables was less, but in a reverse conclusion, no negative influence on 
general cow health or performance was noticed. Whether treatment impacted physiologically 
decreased insulin sensitivity could not be finally clarified, as for the present investigation 
RQUICKI seemed to be too imprecise for reliable statements and further research will be 
necessary to fill the gap of knowledge. For that and other similar projects, the animal model of 
subclinical ketosis will be useful. At this, the classification of cows with a lower and higher BCS 
during dry period, accompanied by a high energetic feeding management a.p. and feed restriction 
p.p. for those of higher BCS, caused an increased lipolysis and ketogenesis soon after calving.  
Owing to the model of subclinical ketosis, further investigations of the metabolism of transition 
cows, as well as diagnosis, treatment and prevention of metabolic disorders are possible.  
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7. Summary 
The time between late gestation and early lactation, also called the periparturient period or 
transition period, is of critical importance for high-yielding dairy cows in terms of health and 
performance. This period is characterized by numerous physiological challenges and a catabolic 
state, as the required energy for milk and maintenance cannot be covered only by voluntary feed 
intake alone. The dairy cow mobilizes energy from body reserves (mainly fat) and passes through 
a distinct negative energy balance (NEB). During NEB, high concentrations of non-esterified 
fatty acids (NEFA) and β-hydroxybutyrate (BHB) are detectable in blood. Because BHB is the 
most stable ketone body in blood, it is usually used to define a ketotic status, with 1.2 mM BHB 
in serum as cut-off point for subclinical ketosis. Concentrations of BHB ≥ 3.0 mM, accompanied 
by clinical signs, are indicative for clinical ketosis. The first aim of the present dissertation was to 
induce subclinical ketosis in lactating cows. Owing to a classification of cows with a lower and 
higher body condition score (BCS; 2.61 ± 0.09 versus 3.19 ± 0.09; P < 0.05) 6 weeks before 
expected calving, accompanied by feeding an energy-dense ration a.p. (7.7 MJ NEL/kg dry 
matter) and feed restriction p.p. for the cows of the higher BCS group, an excessively stimulated 
lipomobilisation was induced. In sum, 80% of the cows in the higher BCS group had ketosis 
(81% subclinical and 19% clinical ketosis), with significantly higher serum concentrations of 
BHB, NEFA and liver-function enzymes (e.g. aspartate transaminase), as well as a higher liver 
lipid content in the 2
nd
 week p.p. (154 mg/g) compared to cows of the lower BCS group, which 
stayed apparently healthy during the experimental trail. For assessing insulin sensitivity, which is 
known to decrease around calving, the revised quantitative insulin sensitivity check index 
(RQUICKI) was used as surrogate marker, but remained unaffected by the ketotic status. 
Variables about immune function were slightly influenced by subclinical ketosis; expect that in in 
vitro tests peripheral blood mononuclear cells (PBMC) of cows not pre-stressed by subclinical 
ketosis in vivo responded more sensitively to increasing levels of BHB as evidenced by both, the 
proliferative capability and the increased release of nitric oxide in the PBMC supernatant. The 
results indicate that even slightly diminished immune cell responsiveness might imply an 
immunosuppression during the periparturient period. Moreover, the proliferative capability of 
PBMC decreased with increasing BHB concentrations in vitro. First significant effects were 
shown at 5 mM BHB. The results confirmed statements that beside NEFA, BHB also elicits 
effects of immune cells. 
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As the metabolic situation of cows during the periparturient period has some similarities to type 
II diabetes and non-alcoholic fatty liver in humans, another aim of the dissertation was to 
investigate how the inhibition of dipeptidyl peptidase-4 (DPP4) affects variables associated with 
NEB and subclinical ketosis. DPP4 inhibitors are successfully used to treat type II diabetes in 
humans, as they improve insulin sensitivity and glucose tolerance, while accumulation of hepatic 
fat is decreased. DPP4 is known to be an incretin hormones (e.g. glucagon-like peptide-1; GLP-
1) degrading enzyme. Therefore, beneficial effects of DPP4 inhibition result from the prolonged 
effectiveness of incretins. Enables by the cooperation with Boehringer Ingelheim we were able to 
test the DPP4 inhibitor BI 14332. With the first occurrence of serum BHB ≥ 1.2 mM 
concentrations BI 14332 was administered daily for 7 days (intravenous, 0.3 mg/kg body weight). 
Treatment with BI 14332 did not alter main markers of ketosis (BHB, liver lipid content), but 
triglycerides and NEFA concentrations in blood were decreased after the treatment, with 
triglyceride values as low as in metabolically healthy cows. Caused by the decreased NEFA 
concentrations, even RQUICKI changed, so that improved insulin sensitivity was assumed. 
Therefore, the prolonged retention period of incretin hormones may impact pathways of energy 
metabolism positively, resulting in a reduced NEB-induced lipolysis. Unfortunately, RQUICKI 
as marker for insulin sensitivity seemed to be insufficiently precise within the present 
experimental design. Considering various hematological and immune-related variables, 
differences between cows with subclinical ketosis treated with BI 14332 and those who remained 
untreated were limited to the lymphocyte CD4
+
/CD8
+
 ratio for which a trend to decreased values 
in the treated animals was noted. The results indicated that the peripartal immune dysregulation 
in ketotic cows was ameliorated by BI 14332.  
In brief, the inhibition of DPP4 had some advantages in the periparturient cow and provided new 
knowledge in animal science, then stimulating further research to clarify the specific interaction 
of incretin hormones and DPP4, as well as its inhibition, in the dairy cow. A further point of 
entry may refer to the positive impacts on insulin sensitivity via DPP4 inhibition. Therefore, 
more sensitive methods to evaluate and to confirm the statements made by RQUICKI are 
necessary. For future research projects, the described animal model for subclinical ketosis will be 
useful in assessing new metabolic pathways, on biochemical and cellular level, and also to 
develop new approaches related to diagnosis, treatment and prevention. 
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8. Zusammenfassung 
Die Wochen um die Abkalbung stellen für den Stoffwechsel einer Milchkuh eine besondere 
Herausforderung dar. Während dieser Zeit, die auch als peripartale Phase bezeichnet wird, ist die 
Futteraufnahme physiologisch gemindert. Gleichzeitig steigt durch die Trächtigkeit, die 
Ausbildung des Euters und die Milchbildung der Energiebedarf. Die Kuh gerät in eine katabole 
Stoffwechsellage. Über den Abbau körpereigener Energiereserven (vornehmlich Depotfett) wird 
das Energiedefizit möglichst ausgeglichen. Wie groß das Energiedefizit und die daraus 
resultierende negative Energiebilanz (NEB) sind, definiert sich u.a. über die Konzentration an 
nicht veresterten Fettsäuren (NEFA) im Blut. Bei anhaltend hoher Lipolyse erfolgt in der Leber 
eine vermehrte Bildung von Ketonkörper, wobei β-Hydroxybutyrat (BHB) als der bedeutendste 
„Ketonkörper“ erachtet wird und als Indikator für subklinische (BHB-Konzentration im Blut > 
1.2 mM) und klinische Ketosen (BHB-Konzentration im Blut > 3 mM) gilt. Ziel der vorliegenden 
Dissertation war die Schaffung eines Tiermodells zur Induktion subklinischer Ketosen bei der 
Milchkuh, um unter kontrollierbaren Bedingungen den ketotischen Stoffwechsel und mögliche 
Auswirkungen auf Leistungsparameter und die Immunantwort zu untersuchen. Dabei wurden 20 
Kühe (primi- und pluripare Tiere) mit einer Körperkondition (BCS) von mindestens 3.0 für die 
letzten 6 Wochen der Trächtigkeit mit einer hochenergetischen Futterration versorgt (7.7 MJ 
NEL/kg Trockenmasse). Post partum erfolgte eine verzögerte Steigerung der Energiezufuhr über 
die ersten 3 Wochen um die postpartale Lipolyse zusätzlich zu stimulieren. Insgesamt wiesen 
80% dieser Kühe eine Ketose auf (81% subklinische, 19% klinische Ketose), gekennzeichnet 
durch signifikant höhere Blutkonzentrationen an BHB und NEFA, sowie deutlich erhöhte 
Leberfettwerte (154 mg/g) im Vergleich zur Kontrollgruppe. Die Kontrolltiere (n = 10) hatten 
zum Zeitpunkt der Einteilung (6 Wochen a.p.) einen BCS < 3.0 und wurden im Versuchsverlauf 
adäquat (entsprechend der Leitlinien der Gesellschaft für Ernährungsphysiologie) gefüttert, so 
dass 90% der Tiere p.p. anhand klinisch-chemischer Variablen als metabolisch gesund eingestuft 
werden konnten. Die Insulinsensitivität, die um die Abkalbung herum physiologisch abnimmt, 
wurde anhand eines Ersatzmarkers, dem sogenannten RQUICKI (revised quantitative insulin 
sensitivity check index), bestimmt. Hierbei konnten keine Unterschiede zwischen Kühen mit und 
ohne subklinischer Ketose festgestellt werden. Im Hinblick auf die Immunantwort zeigten die 
durchgeführten in vitro Untersuchungen, dass die mononukleären Zellen des peripheren Blutes 
(PBMC) der metabolisch gesunden Kühe sensibler auf ansteigende BHB-Konzentrationen 
ZUSAMMENFASSUNG   
 
87 
 
reagierten. Dies konnte durch die Proliferationsfähigkeit der Zellen und die Stickoxid-Freisetzung 
im PBMC-Überstand festgestellt werden. Die Ergebnisse lassen rückschließen, dass bereits leicht 
verminderte Immunzellreaktionen eine Immunsuppression während der peripartalen Phase 
implizieren, so dass das Risiko für Folgeerkrankungen, besonders für Infektionserkrankungen, 
steigt. Des Weiteren sank die Proliferationsfähigkeit der PBMC bei BHB-Konzentrationen in 
Blut ab 5 mM (in vitro). Hier bestätigt sich, dass neben NEFA auch BHB Immunzellreaktionen 
beeinflusst.  
Da die Stoffwechsellage peripartaler Kühe Ähnlichkeiten mit dem Krankheitsbild bei Typ 2 
Diabetes und (nicht alkoholbedingter) Fettleber aufweist, bestand ein weiteres Ziel dieser Arbeit 
darin, zu untersuchen wie sich die Inhibierung der Dipeptidylpeptidase-4 (DPP4) auf ausgewählte 
Parameter der NEB und subklinischen Ketose auswirkt. Dipeptidylpeptidase-4 ist ein Enzym im 
Inkretinstoffwechsel. Das Inkretinhormon Glucagon-like-peptide 1 (GLP-1) wird mit der 
Nahrungsaufnahme aus dem Dünndarm freigesetzt. Im Pankreas bewirkt es eine Stimulation der 
Insulinproduktion bei gleichzeitiger Reduzierung der Glucagonbildung. Innerhalb weniger 
Minuten nach der Nahrungsaufnahme wird GLP-1 durch DPP4 in eine inaktive Form überführt. 
DPP4-Inhibitoren bewirken, dass aktives GLP-1 länger wirken kann, was bei Mensch und Nager 
zu einer Verbesserung der Insulinsensitivität und Glucosetoleranz führt, während 
Fetteinlagerungen in der Leber reduziert sind. Im vorliegenden Versuch wurden subklinisch 
ketotische Kühe mit dem DPP4-Inhibitor BI 14332 behandelt (Boehringer Ingelheim, tägliche 
intravenöse Injektion über 7 Tage, Dosis: 0.3 mg/kg Lebendmasse). Anhand der Ergebnisse 
konnte festgestellt werden, dass die Hauptmerkmale einer ketotischen Stoffwechsellage (BHB, 
Leberfettgehalt) unbeeinflusst von der DPP4-Hemmung via BI 14332 blieben. Allerdings waren 
NEFA- und Triglyceridkonzentrationen im Blut mit Behandlungsabschluss reduziert und sanken 
im Fall der Triglyceride auf ein ähnliches Niveau wie bei metabolisch gesunden Kühen zum 
gleichen Zeitpunkt. Aufgrund der reduzierten NEFA-Konzentration im Blut war RQUICKI 
erhöht, weshalb eine Verbesserung der Insulinsensitivität angekommen werden könnte. 
Allerdings zeigten die durchgeführten Untersuchungen auch, dass RQUICKI möglicherweise 
nicht ausreichend sensibel war um im vorliegenden Fall konkrete Aussagen über die 
Insulinsensitivität zu treffen. Hinsichtlich ihres Immunsystems wiesen BI 14332 behandelte Tiere 
einen tendenziell kleineren CD4
+
/CD8
+
 Quotienten auf, verglichen mit den unbehandelten Tieren 
der Kontrollgruppe. Bei den Kontrolltieren stieg der Quotient im Beobachtungszeitraum auf > 3.0 
an. Im selben Zeitraum verblieb der Quotient bei behandelten Tiere auf einem niedrigeren Niveau 
ZUSAMMENFASSUNG   
 
88 
 
und stieg p.p. nicht an. Diese Ergebnisse deuten an, dass eine mögliche Immundysregulation bei 
Kühen mit subklinischer Ketose durch die DPP4-Inhibierung positiv beeinflusst wurde.  
Zusammenfassend bleibt zu sagen, dass durch die Hemmung der DPP4 wenige, aber positive 
Effekte in der peripartalen Phase gezeigt werden konnten. Weiterführende Studien könnten hier 
anknüpfen und den noch wenig erforschten Zusammenhang zwischen GLP-1 und DPP4, sowie 
deren Inhibierung, bei der Milchkuh genauer untersuchen. Des Weiteren muss die 
Insulinsensitivität stärker berücksichtigt und mögliche positive Einflüsse mit sensibleren 
Methoden festgestellt werden, auch um die in dieser Dissertation gezeigten Ergebnisse mittels 
RQUICKI bestätigen zu können. Für solche und ähnliche Forschungsvorhaben stellt das 
Tiermodell zur Induktion subklinischer Ketosen eine adäquate Voraussetzung dar und bietet im 
Rahmen der Tiergesundheit neue Forschungsmöglichkeiten mit Bezug auf Diagnose, Prävention 
und Therapie von Milchkühen im peripartalen Zeitraum. 
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